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Polymeric nanoparticles from amphiphilic copolymers are deemed as flexible 
platforms for effective delivery of chemotherapeutic drugs to tumor tissues. The use of 
cholesterol as the hydrophilic segment can confer stability upon dilution and high drug 
loading capacity to these type of nanoparticles due to the tendency of cholesteryl 
groups to aggregate and form liquid crystal phases. On the other hand, the 
incorporation of polyethylene glycol as the hydrophilic block provides colloidal stability 
and reduced opsonization. Building on previous research in the laboratory, the overall 
goal of the present dissertation was to further advance the development and 
understanding of novel and rationally designed cholesterol-based polymeric 
nanoparticles as delivery systems to improve the therapeutic index of highly toxic 
anticancer drugs. 
Two types of cholesterol-based nanoparticles encapsulating the anticancer drug 
doxorubicin were developed and comprehensively evaluated in this study. The first type, 
formed by an amphiphilic brush-like block copolymer, displayed significant tumor growth 
inhibitory activity in a mouse model and an improved safety profile compared to the free 
form of the drug. However, slow drug release seemed to prevent this formulation from 
displaying better efficacy results.  
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As a solution to the drug release pitfall, a second type of nanoparticle was 
developed, incorporating a cleavable (redox-sensitive) disulfide bond in the polymer 
structure to facilitate bioresponsive drug release inside cancer cells overexpressing the 
reducing scavenger molecule glutathione. Evidence of the significant influence of the 
method of preparation on the characteristics and performance of these doxorubicin-
loaded redox-sensitive polymeric nanoparticles was observed, underlying the relevance 
of implementing systematic approaches like quality by design (QbD) to the development 
of nanomedicines. On the other hand, proof of the cleavable nature of these second-
generation nanoparticles and superior in vitro performance compared to the non-
cleavable platform was obtained, as well as evidence of their in vivo efficacy and 
improved safety profile when evaluated against free doxorubicin (DOX-HCl) and the 
commercial pegylated liposomal form (Doxil®) 
These findings support future translational efforts regarding the developed redox-
sensitive cholesterol-based polymeric nanoparticles as carriers to improve the 
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Cancer is a group of diseases characterized by abnormal cells that divide 
uncontrollably, invading nearby tissues and spreading to other parts of the body. It is the 
third most common cause of death worldwide and it accounts for 22% of all deaths in 
the US [1]. The most widespread form of cancer treatment is chemotherapy, the use of 
cytotoxic compounds to kill cancer cells. However, despite the undeniable benefits of 
chemotherapeutic drugs, their clinical use is often limited by toxicity; the non-specific 
nature of their mechanism of action can lead to damage of normal cells specially those 
rapidly dividing.  
Nanocarriers harbor the potential to deliver highly toxic anticancer drugs to 
tumors while limiting the exposure of healthy organs where severe or even life-
threatening adverse effects can occur. This research field, known as cancer 
nanomedicine, has made significant contributions to the cancer treatment toolbox in the 
past three decades, with five FDA approved products and four more currently in use in 
Europe and Asia [2]. Most of these approved products are liposomal-based, due in part 
to the advantages associated with liposomes like biocompatibility and stability. 
However, as the field evolves several challenges to effective translation have been 
identified and more chemically versatile platforms, other than liposomes, are required to 
address them. Among the diverse landscape of nanocarriers, polymeric nanoparticles 
from amphiphilic block copolymers are deemed as flexible and tunable delivery 
platforms that efficiently incorporate hydrophobic drugs and can be tailored to display 
long term plasma circulation, effective extravasation across the leaky tumor vasculature 
and tissue-specific drug release [3, 4].  
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In order to provide biocompatible, stable and versatile delivery platforms to 
address the toxicity issues associated with conventional chemotherapy and overcome 
the pitfalls of other carriers , we previously reported the synthesis and characterization 
of an amphiphilic block copolymer composed of cholesterol, as the hydrophobic 
segment, and polyethylene glycol, as the hydrophilic block (P(NBCh9-b-NBPEG)) 
(Figure 1.1). A brush-type architecture was incorporated into this polymer to confer 
stability and high drug loading to the formed nanoparticles. In this case, several 
segments of cholesterol and several segments of PEG were attached to a common 
polynorbornene backbone. This polymer self-assembled into stable nanostructures that 
encapsulated the anticancer drug doxorubicin (DOX-NPs), with high drug loading (˷ 
20%) [5]. DOX-NPs displayed in vitro sustained drug release kinetics, effective 
internalization by human cancer cells and concentration-dependent cytotoxic activity. 
Additionally, stability upon injection and long plasma circulation were observed.  Initial 
biodistribution studies showed that DOX-NPs accumulated in tumor tissue and reduced 
the exposure of vital organs to doxorubicin when compared with the non-encapsulated 
doxorubicin hydrochloride form (DOX-HCl).  
On the other hand, slow and incomplete drug release in tumor tissues is a 
common concern for polymeric nanoparticles. To provide tissue-specific drug release, a 
cholesterol-based block copolymer with a reducible disulfide bond (PC5MA-SS-PEO) 
was also designed and synthesized (Figure 1.2) [6]. It is expected that high tumor 
glutathione (GSH) concentrations (10 mM -20 mM) lead to the reduction of the disulfide 
bond in the polymer structure followed by nanoparticle disruption and subsequent drug 
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release while low drug release in plasma is guaranteed by naturally low extracellular 
GHS concentrations (10 µM). 
 
 
Figure 1.1. Cholesterol-based brush-like block copolymer (P(NBCh9-b-NBPEG)). 
 
Figure 1.2. Redox-sensitive cholesterol-based block copolymer (PC5MA-SS-PEO). The 





1.2 Objectives and aims 
The overall goal of the present dissertation is to further advance the development 
and understanding of these novel and rationally designed cholesterol-based polymeric 
nanoparticles as delivery systems to improve the therapeutic index of highly toxic 
anticancer drugs. 
Specific aims 
The specific aims of the project were: 
Specific aim 1. To evaluate the efficacy and toxicity of DOX-NPs in a mouse 
xenograft human tumor model and compare its effects with the non-encapsulated 
form of the drug (DOX-HCl).  
Specific aim 2. To prepare doxorubicin-loaded redox-sensitive polymeric 
nanoparticles (DOX-SS-NPs) with optimal characteristics for in vivo administration.  
Specific aim 3. To assess the redox-triggered in vitro drug release, cytotoxicity, 
intracellular distribution and storage stability of DOX-SS-NPs and select the most 
promising formulation to advance in the development process.  
Specific aim 4. To evaluate the biodistribution, efficacy and toxicity of DOX-SS-NPs 
in a mouse xenograft human tumor model and compare its effects with DOX-HCl 
and the commercial pegylated liposomal form (Doxil®).  
 
1.3 Chapter organization and outline  
Chapter 2 reviews the thermodynamic and kinetic principles behind the 
formation of polymeric nanoparticles from amphiphilic block copolymers as well as the 
most common methods of preparation. The advantages of the use of this type of 
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colloidal aggregates as delivery platforms for chemotherapeutic drugs are also 
highlighted.  Subsequently, the concept of bioresponsive materials to facilitate drug 
release from polymeric nanoparticles is introduced along with a literature review about 
redox-sensitive nanomedicines. Finally, a description of the available doxorubicin 
commercial products is provided, emphasizing the need for better formulations.  
Giving previous encouraging results regarding the favorable biodistribution of 
doxorubicin (DOX) when administered in cholesterol-based polymeric nanoparticles 
(DOX-NPs), chapter 3 assesses if the observed higher drug concentrations in tumors 
tissues and lower concentrations in healthy organs, when comparing to DOX-HCl, could 
translate into increased in vivo efficacy and reduced toxicity. In this chapter, a mouse 
xenograft human tumor model is used to evaluate the effect of DOX-NPs on tumor 
growth, survival and multi-organ toxicity.  
Chapter 4 studies the impact of the method of preparation on the characteristics 
of DOX-loaded redox-sensitive nanoparticles (DOX-SS-NPs). According to literature 
reports, the method of preparation can have a significant effect on the properties of 
drug-loaded polymeric nanoparticles from amphiphilic copolymers since the assembly of 
these systems is a kinetically controlled process. In order to obtain nanoparticles with 
optimal particle size distribution, shape and drug loading we compare two common 
methods of preparation: 1) Cosolvent removal method and 2) O/W emulsion method. 
The effect of formulation parameters is also investigated using a design of experiments 




Chapter 5 is a comprehensive in vitro testing of two selected redox-sensitive 
formulations and highlights the extension of the impact of the method of preparation 
beyond the characteristics of the nanoparticles to the in vitro performance of the 
formulations.  This chapter studies the redox-triggered nature of drug release from the 
carriers as well as the effect of DOX-SS-NPs on the viability of human cancer cells.  To 
further confirm drug release in biologically relevant conditions, the intracellular 
distribution of the drug when administering DOX-SS-NPs is also assessed. Lastly, 
chapter 5 evaluates the long term stability of the formulations at 4°C. DOX-HCl and 
Doxil® are tested in most experiments described above for comparison. DOX-NPs, the 
non-cleavable nanoparticles evaluated in chapter 3, are included in the cytotoxicity and 
intracellular distribution studies to establish the potential advantages of a cleavable 
(redox-sensitive) carrier vs a non-cleavable one.  
The biodistribution of the redox-sensitive nanoparticles is evaluated in chapter 6 
to confirm tumor accumulation and as a criteria to select the final formulation for in vivo 
efficacy studies. Once the best formulation is identified, a dose tolerability study is 
conducted in healthy mice to determine the dose of DOX-SS-NPs that allowed for 
repeated administrations without life-threatening side effects, the optimal doses of DOX-
HCl and Doxil® are also established in this chapter. Finally, the effect of DOX-SS-NPs 
on tumor growth, survival and multi-organ toxicity is evaluated in a mouse xenograft 
human tumor model and compared to the effect of DOX-HCl and Doxil®. 
Chapter 7 summarizes the findings of each chapter and presents the overall 
conclusions of the thesis. A perspective on future steps and challenges is also provided 
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Chapter 2.   
Polymeric Nanoparticles from Amphiphilic Block Copolymers and their 























 2.1. Abstract 
Nanomedicines harbor the potential to improve the therapeutic index of toxic 
anticancer drugs. Among the numerous types of nanocarriers, polymeric nanoparticles 
from amphiphilic block copolymers stand out due to the possibility of carefully selecting 
the hydrophobic and hydrophilic segments to confer colloidal stability, high drug loading 
and long plasma circulation. Besides, thanks to the diversity in synthetic polymer 
chemistry, bioresponsive segments can be introduced to promote drug release in tumor 
tissues. This chapter discusses the role of nanomedicines in cancer treatment as well 
as the advantages of using nanomedicines based on amphiphilic block copolymers. 
Finally, details about the development and clinical performance of Doxil®, the first 
approved nanomedicine, are introduced to highlight its advantages and unmet 
expectations.  
 
2.2. Nanomaterials and their applications in medicine 
Materials in the nanoscale dimensions, 1-100 nm, display unique characteristics 
such as large surface area to mass ratio and prevalent quantum effects that make them 
very attractive for applications in electronics, catalysis and insulation among others [1].   
Interest regarding the use of nanomaterials in medicine rises from the fact that 
biological processes inside the human body occur at nanoscale dimensions, opening 
the possibility of developing very tunable and precise diagnostic and therapeutic tools. 
The early 1960s idea of nanomedicine envisioned tiny machines performing surgery at 
the cellular and even molecular level [2]. As the field evolved over the years, drug 
delivery, imaging contrast agents and biomarker detection became its most promising 
11	
	
areas in terms of successful clinical translation [3]. It is important to highlight that from 
the FDA point of view, products that involve the application of nanotechnology can also 
be those that contain materials with similar dimension-dependent properties even if they 
are outside the typical nanoscale range, up to 1000 nm [4].  
Delivering therapeutic agents using nanomaterials, combinations known as 
nanomedicines, mainly intends to alter the drug pharmacokinetics and biodistribution to 
ultimately modify their efficacy and/or toxicity [5]. A group of diseases where this 
approach has proven particularly attractive is cancer, mainly because of the severe 
toxicity of conventional chemotherapy and the overall low treatment response in certain 
malignancies.  
 
2.3. Nanomedicines in cancer treatment 
The introduction of chemotherapy in the 1940’s was a major breakthrough for 
cancer treatment: remissions were possible for the very first time and the life 
expectancy of patients significantly increased [6]. However, despite its undeniable 
benefits, chemotherapy damage to healthy organs can lead to severe, even life-
threatening side effects. High prevalence of cancer and the limitations of conventional 
chemotherapy create the need for selective treatments that can effectively kill cancer 
cells with minimal effects on normal cells.  
Nanocarrier mediated drug delivery is an increasingly widespread strategy to 
improve the efficacy and decrease the toxicity of chemotherapeutic drugs [7]. Since the 
approval of the first anticancer nanomedicine by the FDA in 1995, five other products 
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have been introduced to the market while both preclinical and clinical research have 
intensified [8].   
As previously stated, nanomedicines are designed to alter the biodistribution and 
pharmacokinetic profile of small molecules and enable their selective delivery to the 
diseased tissue. Despite recent controversy [9-11], the enhanced permeability and 
retention (EPR) effect is still considered the most important principle for the delivery of 
macromolecules and nanomedicines to solid tumors. Large amounts of oxygen and 
nutrients are required to sustain rapid cell division. In order to meet those metabolic 
requirements, cancer cells overexpress proteins that promote the formation of new 
blood vessels like the vascular endothelial growth factor (VEGF). This accelerated 
angiogenic process leads to irregular tumor vasculature characterized by tortuous 
architecture and high permeability. Widened cell junctions and increased numbers of 
fenestrations allow macromolecules and nanomedicines to extravasate from the 
bloodstream to tumor tissues, a process that is strictly regulated in normal tissues. On 
the other hand, there are no functional lymphatic vessels inside solid tumors and those 
in the tumor margin often display retrograde flow [12]. As a result, macromolecules and 
nanomedicines are retained in tumors, a phenomenon known as the EPR effect or 
passive targeting [13]. Due to their size, the transport of nanomedicines across 
continuous endothelium is minimal, which makes their accumulation in healthy organs 
much lower than the accumulation of small molecules that in contrast can easily diffuse 
across continues vasculature. By taking advantage of the selective accumulation of 
nanocarriers in tumor tissues, these platforms can deliver drugs to solid tumors and 
reduced the exposure of off-target organs to highly toxic anticancer drugs.  
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There are several requirements for the development of successful antineoplastic 
nanomedicines. To effectively accumulate in tumors, nanomedicines should display 
stability upon intravenous administration, long term blood circulation, and adequate 
particle size and shape to cross the gaps in the tumor vasculature [14]. Additionally, to 
further ensure nanomedicine safety and efficacy, the nanocarrier should be 
biocompatible, ideally display high drug loading and controlled drug release kinetics. 
Finally, from the manufacturing perspective nanomedicines should be easy to fabricate 
and sterilize.  Liposomes, solid lipid nanoparticles and inorganic nanoparticles are some 
of the several nanocarriers described in the literature [15]. Aggregates in the nanoscale 
range made from synthetic or natural polymers have also been used for the formulation 
of nanomedicines. Thanks to the diversity in synthetic polymer chemistry, these 
aggregates are flexible deliver platforms that can be tailored to display the 
characteristics required for effective tumor accumulation and optimal drug release in 
tumor tissues.  
 
2.3.1. Effect of nanoparticle properties on nanomedicine performance  
The successful application of nanoparticle drug delivery in cancer treatment 
partially depends on key characteristics of the formulated nanocarriers. Particle size 
affects the biodistribution, clearance and tumor accumulation of long-circulating 
nanocarriers. Particles below 5-6 nm display short plasma circulation due to rapid renal 
filtration [16] while particles above 200 nm are quickly cleared from circulation through 
the spleen [17]. Longer plasma circulation usually translate into higher tumor 
accumulation through the EPR effect, being particles between 50 nm - 100 nm the ones 
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displaying the best accumulation in highly vascularized and permeable tumors [18]. On 
the other hand, accumulation in poorly permeable tumors seems to be better for 
particles between 30 and 50 nm as previously discussed by Cabral et al [19].  
The shape of a nanoparticle can also affect its transport in the circulation and its 
interaction with cell membranes.  One of the main steps determining the transport of 
flowing nanoparticles to tumors is their margination towards the walls of tumor blood 
vessels. Nanoparticles have to interact with the tumor vascular bed to move from the 
lumen of the vessels to the neoplastic tissues. Because nanoparticles are mainly 
transported by convection in the tumor microcirculation, spherical nanoparticles are less 
likely to drift towards the vessel walls than oblated-shape nanoparticles. Elliptical 
nanoparticles experience torques resulting in tumbling and rotation, which increase 
margination and facilitates tumor accumulation [20]. On the other hand, spherical 
nanoparticles are more easily internalized by macrophages and cancer cells than 
geometries with high aspect ratio which subsequently affects their biodistribution and 
therapeutic efficacy [20]. Although it is clear that shape is an important attribute of 
nanoparticles, there are not conclusions regarding the best geometry and 
comprehensive studies correlating shape, biodistribution and efficacy are needed.  
Drug loading, defined as the amount of drug in the formulation as a percentage 
of total weight, is another important characteristic of nanomedicines. From the 
manufacturing perspective, higher drug loading is preferable because less excipients 
are used to encapsulate the same quantity of active pharmaceutical ingredient (API). 
Increasing drug loading decreases the number of nanoparticles that need to be 
manufactured to deliver an equivalent dose of API which in turns reduces manufacturing 
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cost and processing time. Injecting a lower amount of carrier is also desirable from the 
safety point of view. Additionally, maximizing drug loading may increase the chances of 
high drug concentrations in tumor tissues.  
 
2.4. Nanoparticles from amphiphilic block copolymers 
A unique type of polymeric aggregates are those formed by amphiphilic block 
copolymers. Amphiphilic block copolymers contain more than one type of monomer, 
commonly one hydrophilic and one hydrophobic so that the resulting macromolecule 
displays regions of opposite behavior in their interaction with aqueous media. The 
location of these segments is sequential, meaning a clearly hydrophilic region is 
followed by a hydrophobic one in opposition to random copolymers in which the 
probability of a given segment at any given location is independent of the nature of the 
adjacent segment. Once these amphiphilic copolymers reach certain concentration in 
water, their hydrophobic segments come together and remove themselves from the 
aqueous solvent giving rise to colloidal aggregates, this is a spontaneous process 
driven by an increase in the entropy of the surrounding water molecules also known as 
the hydrophobic effect. Depending on the molecular weight of the polymer, the size of 
the hydrophobic and hydrophilic segments and the interfacial tension between the 
hydrophobic segment and water these aggregates can arrange into polymeric micelles, 
polymeric nanoparticles or polymersomes. The structures above are typical of 
copolymers with two consecutive blocks since polymers with three or more alternate 
blocks can form other type of aggregates.  
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Polymeric micelles display a spherical, core/shell structure where the core is 
formed by the hydrophobic segments of the polymer chains and the shell is formed by 
the hydrophilic fragments. In analogy to small molecular weight lipid surfactants, 
polymeric micelles are dynamic association colloids since the polymer chains in the 
aggregates are at equilibrium with the polymer chains in the continuous phase. 
Therefore, they are not considered solid particles. In order to form polymeric micelles 
the interfacial tension between the hydrophobic segment and water must be low enough 
to allow polymer chains to leave the micelle, exposing its lipophilic region to the 
aqueous solvent. Other factors such as steric hindrance between the chains in the core 
and in the shell may also play a role on determining if there is a relevant dynamic 
exchange of polymer chains between the aggregates and the solvent [21]. Polymeric 
micelles displayed a mobile fluid-like core in which hydrophobic drugs can be 
solubilized. 
On the other hand, polymeric nanoparticles from amphiphilic block copolymers, 
also known as nanospheres, display the same core/shell structure of polymeric micelles 
but their core is solid-like in nature. In this case, dynamic equilibrium is absent and the 
aggregates are rather kinetically frozen due to the high energy penalty of a polymer 
chain leaving the aggregate [21, 22]. When the interfacial tension between the 
segments in the core and the aqueous media is high, block-copolymers will form 
polymeric nanoparticles instead of micelles. Nanospheres can be seen as solid 




A third type of aggregates from amphiphilic block copolymers are polymersomes. 
Polymersomes are spherical vesicles formed by a water inner phase surrounded by a 
polymeric bilayer. In the bilayer, the hydrophilic segments of the polymer face the 
internal and external water phases while the hydrophobic segments constitute the inner 
part of the membrane. Polymersomes are usually formed by polymers in which the 
hydrophilic segment accounts for 10-40% of the total polymer mass and the interfacial 
tension between the hydrophobic segment and the aqueous media is high [23]. As 
analogous to liposomes, polymersomes find utility in the encapsulation of water soluble 
drugs which can be entrapped in the aqueous inner compartment. 
The flexibility provided by amphiphilic block copolymers in terms of the diverse 
nanostructures that can be obtain is one of the reasons why there is wide spread 
interest in their use for drug delivery. In the present work, we focus on the development 
of polymeric nanoparticles from amphiphilic block copolymers for the delivery of potent 
anticancer drugs to tumor tissues since there are many advantages related to their use 
in cancer nanomedicine. First of all, the hydrophilic shell in polymeric nanoparticles 
provides compatibility with the aqueous environment and reduces the internalization by 
cells of the reticuloendothelial system (RES) while strong interactions between the 
segments in the hydrophobic core lead to low critical aggregation concentration (CAC) 
values (10-6 – 10-8 M) and subsequent stability upon dilution in the blood stream. 
Furthermore, the hydrophobic core permits the effective incorporation of drugs with low 
water solubility. On the other hand, their size range (10 nm- 200 nm) allows them to 
cross the tumor vasculature while preventing renal filtration [24, 25].  
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The stability of this type of polymeric nanoparticles in storage and upon 
administration is largely affected by the interactions among the segments in the 
hydrophobic core. Because of the strong tendency for self-association of cholesteryl 
groups, as well as their structural rigidity and biocompatibility self-assembled polymeric 
nanoparticles with cholesterol core have been investigated for drug delivery applications 
in the past [26-28].  
 
2.4.1. Cholesterol as the hydrophobic segment of amphiphilic block copolymers  
Cholesterol is a lipid molecule of the sterol class with a paramount biological 
role. As a major component of animal cell membranes, cholesterol regulates membrane 
fluidity and permeability; cell membranes with high cholesterol content, such as the 
ones in the epidermis, have high stability and low permeability. It also serves as a 
precursor for steroid hormones, bile acids and vitamin D. The ring structure of 
cholesterol make it a planar and rigid molecule (Figure 2.1). Due to its alkyl chain, 
cholesterol is mostly hydrophobic but the hydroxyl group in one of the cyclohexane rings 
confers it a weakly amphiphilic character. This hydroxyl group also facilitates chemical 
modifications and conjugations such as the formation of cholesteryl esters when 
reacting with acetyl halides.  
Both small molecules and macromolecules bearing cholesteryl groups can 
self-assemble into liquid crystal mesophases, a phenomenon first described in 1888 by 
the Austrian scientist Friedrich Reinitzerwhile while working on the physicochemical 
properties of cholesteryl benzoate. Liquid crystal mesophases display extensive order in 
the molecular scale that can extend to form domains in the micrometer range but does 
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not reach macroscopic dimensions as observed in crystals. Using cholesteryl groups as 
the hydrophobic building blocks in amphiphilic block copolymers is an interesting 
approach given their ability to self-assemble through hydrophobic interactions and form 
liquid crystal mesophases, promoting the self-assembly of the polymer chains and 
providing great stability to the aggregates. In that way, a water soluble polymer like 
polyethylene glycol (PEG) can be modified into an associative polymer by the addition 
of cholesteryl segments. The strong tendency for self-association of cholesterol and its 
rigidity provides very stable hydrophobic cores once the polymer assembles into 
aggregates [26, 29]. These cholesterol-based aggregates display low CAC values (10-6 
–10-8 M), which favors stability upon dilution in blood circulation, and high drug loading 
(5-15%) [27, 30, 31]. Being a component of cell membranes and precursor of hormones 
and vitamins, cholesterol is a biocompatible material, which make it ideal for 
applications in drug delivery.  
 






2.4.2. PEG as the hydrophilic segment of amphiphilic copolymers  
One of the biggest challenges for nanomedicines in cancer treatment is their 
quick removal from blood circulation by the reticuloendothelial system (RES) via 
recognition of opsonins adsorbed on the particle surface by receptors on the cell 
membranes of phagocytes [32, 33]. Longer circulation time is desirable since it 
increases the probability of the nanomedicine reaching tumor tissues. Coating the 
surface of nanoparticles with hydrophilic polymers, like dextrans or polyglycerols but 
most commonly polyethylene glycol (PEGylation) is a widely spread strategy to reduce 
internalization by the RES [34].  Polyethylene glycol (PEG) is a polymer of ethylene 
oxide (Figure 2.2) also known as polyethylene oxide (PEO) or polyoxyethylene (POE). 
PEGs of different molecular weights (200 g/mol to 500,000, g/mol) are commercially 
available for numerous applications in the food, cosmetic and pharmaceutic industries 
as surfactants, dispersant agents and cosolvents. Due to its hydrophilic nature, PEG 
chains produce a bulky hydration cloud that sterically prevents NPs from interacting with 
blood components like opsonins. Furthermore, the conformational freedom provided by 
the flexibility of PEG makes the interpenetration of proteins into the PEG corona 
thermodynamically unfavorable [35]. On the other hand, the positive interaction between 
PEG and water molecules confers stability to the nanoparticles in aqueous media while 
the bulky nature of hydrated PEG prevents particle size increase over time due to 
nanoparticle aggregation, also known as steric stabilization. Furthermore, PEG has low 











2.4.3. Brush-like amphiphilic block copolymers 
An important category of amphiphilic block copolymers are those with a brush-
type architecture, also known as graft polymers. These polymers are formed by a 
backbone densely grafted with hydrophilic and hydrophobic segments as side chains, 
arranged in a block order (Figure 2.3) [37]. These large domain structures, can confer 
better colloidal stability and biodistribution due to a strong shielding effect provided by 
numerous hydrophobic segments while drug loading can be also high since there are 








2.4.4. Methods of preparation of polymeric nanoparticles from amphiphilic block 
copolymers 
Because polymeric nanoparticles are kinetically trapped systems, their 
characteristics are determined by the method of preparation. Several methods have 
been reported in the literature, being nanoprecipitation and dialysis the most commonly 
used due to their simplicity and the fact that a large energy input such as sonication is 
not required.  
  
2.4.4.1. Cosolvent removal  
Also known as nanoprecipitation or solvent displacement method. It relies on a 
rapid decrease in the quality of the solvent by the addition of water. Initially, both the 
drug and the polymer are dissolved in a water miscible organic solvent (e.g. ethanol, 
acetone or dimethylformamide). This solution is then added to a stirred aqueous phase 
which can only solubilize the hydrophilic segment of the copolymer, triggering the self-
assembly of the hydrophobic segments. Subsequently, the organic solvent is eliminated 
by evaporation or dialysis [38]. Some drug molecules are entrapped during the 
nanoparticle formation process while free molecules can be removed by dialysis or 
ultrafiltration. Parameters like polymer concentration, stirring speed, and the ratio 
organic solvent to water can affect particle size distribution and drug loading. An 
advantage of this technique is that the use of a homogenizer or a sonicator is not 
required, facilitating scale-up and manufacturing. Moreover, many water miscible 
organic solvents are class 3 (i.e. regarded as less toxic by the FDA) and higher residual 
amounts are acceptable [39], contributing to a simpler manufacturing process. On the 
23	
	
other hand, the selection of an adequate organic solvent can be difficult since it needs 
to dissolve both the polymer and the drug [40].   
 
2.4.4.2. O/W emulsion 
In this method, the drug is dissolved in a volatile and non-water miscible organic 
solvent (e.g. dichloromethane or chloroform) to create an emulsion when adding the 
organic phase to water. The polymer can be either dissolve in the organic solvent or 
suspended in the aqueous phase as blank nanoparticles. The formation of the emulsion 
is facilitated by a high energy source (e.g. sonicator or homogenizer). This step is 
critical to the nanoparticle formation. Subsequently, the organic solvent is evaporated by 
stirring the emulsions at room temperature and pressure or under reduced pressure 
[41]. During the formation of the emulsion the amphiphilic polymers will most likely be 
located at the interface between the organic solvent and water. As the solvent 
evaporates, the polymer chains assembly and drug molecules are entrapped in the 
polymer matrix.  Parameters like type of organic solvent, polymer concentration, energy 
source and rate of evaporation can all affect the final nanoparticle characteristics. A 
disadvantage of this method is the use of class 2 solvents (e.g. chloroform and 
dichloromethane) which are known to display inherent toxicity so the allowed residual 
amounts are in the order of 60 – 600 ppm. The use of class 2 solvents require further 
efforts to assure that the final content is below  the residual limits stablished by the FDA. 
In some cases, chloroform and dichloromethane can be replace by ethyl acetate, a 





In this method, the polymer and the drug are dissolved in a water miscible 
organic solvent and the solution is dialyzed against water. The slow replacement of the 
organic solvent with water (i.e. a bad solvent for the hydrophobic block) promotes the 
self-assembly of the polymer chains. During this process some drug molecules are 
entrapped in the core of the nanoparticles while free molecules can be removed during 
dialysis. This method is very popular in laboratory settings, however, it is not suitable for 
large scale production and it tends to produced polydispersed aggregates due to the 
slow change in the quality of the solvent [41].  
 
2.5. Redox-sensitive nanomedicines 
Rapid and complete drug release from nanoparticles at the diseased tissues 
remains challenging, potentially compromising the therapeutic effects of nanomedicines. 
To overcome this drawback, several successful attempts to develop bio-responsive 
nanocarriers have been reported [42]. With this approach, the main goal is to develop 
delivery platforms that can rapidly and selectively release their cargo once exposed to 
specific stimuli within the tumor microenvironment or inside cancer cells to improve the 
efficacy of the nano-therapeutics and the safety profiles via site-specific release of their 
carried drugs.  
Redox-sensitive nanocarriers are of particular interest because of higher GSH 
levels in tumor tissues compared to normal tissues (10—20 mM vs. 0.5—10 mM) [43, 
44] and plasma (1-10 µM) [45], thus enabling the inherent biochemistry of tumors to be 
utilized for therapeutic benefit. A diverse array of nanocarriers including polymeric 
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micelles [46] [47], liposomes [48],  and silica nanoparticles [49] have been designed to 
quickly respond to the intracellular reducing environment to facilitate drug release, 
increase cytotoxicity, and subsequently improve the efficacy of chemotherapeutic drugs 
delivered by nanocarriers.  There is much evidence suggesting that the presence of 
redox sensitive moieties, most commonly disulfide bonds, provides nanoparticles with 
faster drug release and subsequently improved in vitro cytotoxicity.  
Kim et al. incorporated cystamine as a redox-sensitive cross-linker in the core of 
poly(ethylene oxide)-b-poly(methacrylic acid) polymeric micelles to facilitate drug 
release at high intracellular GSH concentrations [50]. In vitro release of the anticancer 
drug doxorubicin (DOX) from this formulation was effectively promoted by GSH and 
cysteine in a concentration-dependent manner. Interestingly, the IC50 of DOX 
encapsulated in redox-sensitive micelles in A2780 ovarian carcinoma cells was 0.12 
µM, while the IC50 of DOX encapsulated in non-redox-sensitive micelles was 0.7 µM, 
confirming the hypothesis that higher cytotoxic activity can be achieved through redox-
triggered drug release.  
A targeted delivery system for the hydrophobic drug paclitaxel (PTX) was 
developed by Li et al. based on redox-sensitive hyaluronic acid-deoxycholic acid (HA-
ss-DOCA) conjugates [51]. Hyaluronic acid (HA) was included as a targeting ligand 
since cancer cells often over-express HA receptors (CD44) on their surface [52]. These 
conjugates aggregate in aqueous media, encapsulating PTX in the hydrophobic core. 
Rapid drug release from HA-ss-DOCA micelles was observed under reducing 
conditions (90% release after 24 h, 20 mM DTT), while little release was detected from 
non-redox-sensitive micelles (HA-DOCA) in the same release media (10% release after 
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24 h). PTX encapsulated in HA-ss-DOCA micelles was more than twice as potent as 
PTX encapsulated in HA-DOCA micelles when measuring in vitro cytotoxicity in MDA-
MB-231 breast cancer cells treated for 72 hours (IC50 0.03 µM vs. 0.07 µM).  
Redox-sensitive nanocarriers containing anticancer drugs not only outperform 
the anticancer activity of their non-sensitive counterparts in vitro, but also in vivo. In 
order to provide structural stability and controlled release through cross-linking, Li et al. 
designed reversible, disulfide cross-linked polymeric micelles composed of PEG, 
dendritic oligolysine, and cholic acid [46]. Cysteine was incorporated into the 
telodendrimers to provide a disulfide cross-link (PEG5k-Cys4-L8-CA8), and the thiol-
free telodendrimer, PEG5k-CA8, was also synthesized for comparison. PTX was 
incorporated into the micelles followed by cross-linking of the cysteine residues by 
oxidation. PTX release from PTX-DCM (cross-linked, redox-sensitive micelles) was 
facilitated as the levels of GSH in the media increased. In the absence of GSH, release 
from PTX-DCM was slower than release from PTX-NCM (non-cross-linked, non-redox-
sensitive micelles). Notably, the tumor growth rate of mice treated with 5 doses of 10 
mg PTX/kg PTX-DCM was significantly lower compared to those treated with the same 
dose of PTX-NCM (percent tumor growth inhibition with respect to the PBS control was 
67% vs. 42%, estimated from the relative tumor volume figure), and both formulations 
were superior to FDA-approved Taxol®.   
In a similar cross-linking approach, Koo et al. obtained redox-sensitive micelles 
via self-assembly of poly(ethylene glycol)-b-poly(Lysine)-b-poly(L-phenylalanine) (PEG-
PLys-PPhe) followed by cross-linking with 3,3'-dithiobis(sulfosuccinimidylpropionate) 
(DTSSP), a disulfide-containing compound [47]. Docetaxel (DTX) release from cross-
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linked micelles increased when GSH was present in the media in a concentration-
dependent manner. The cross-linked, redox-sensitive micelles displayed longer in vivo 
circulation and higher tumor accumulation than their non-cross-linked counterparts. 
Reduction in tumor growth rate was greater in the group treated with the cross-linked 
redox-sensitive formulation than with the non-cross-linked formulation (percent tumor 
growth inhibition with respect to the saline control was 83% vs. 70%, calculated 
estimated from the tumor volume figure). This enhanced in vivo efficacy likely resulted 
from the combination of minimized drug loss in circulation, enhanced accumulation in 
tumor tissues, and rapid intracellular drug release [47].   
Overall, it has been demonstrated by several groups that drugs encapsulated in 
redox-sensitive delivery platforms display greater in vitro cytotoxicity and in vivo efficacy 
than their non-redox-sensitive counterparts. However, in most cases, it is unknown 
where in the cell and how the reduction occurs as well as the factors affecting the 
reaction kinetics.  
The successful clinical translation of redox-sensitive nanomedicines is a complex 
process that involves overcoming multiple challenges [53] such as 1) limited knowledge 
of the off-target effects in organs with high GHS expression, 2) lack of methods of 
preparation that can be scale up to industrial dimensions and 3) unknown variation in 
the GHS expression in human tumors. To address these knowledge gaps, first, it is 
necessary to conduct extensive preclinical research to demonstrate efficacy and safety. 
So far, most in vivo studies have emphasized efficacy evaluation but comprehensive 
safety assessment is lacking. In that sense, organs with high GSH levels and high 
tendencies for nanoparticle accumulation, such as the liver, deserve special attention. 
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Additionally, the use of well-known and traditionally used materials may facilitate the 
achievement of suitable safety profiles and reduced costs of preclinical evaluation, as 
information regarding their in vivo degradation profiles is already available. On the other 
hand, the scale-up phase may be hastened thorough the understanding of process and 
formulation parameters and their effects on the characteristics and performance of the 
nanomedicines early in the research process. The early selection of preparation 
methods that can be used in a manufacturing setting is also a sound approach. Once 
the preclinical phase is completed, the next challenge is the selection of the clinical 
indication and the design of the clinical study. Selection of patients for clinical studies 
based on nanoparticle deposition in tumors as suggested by Lee et al. may increase the 
probabilities of observing positive clinical outcomes [54]. In the particular case of redox-
sensitive nanoparticles, selection of patients can be further complemented by 
determining the tumor redox status through the use of redox-sensitive imaging probes 
[55]. 
 
2.6. Doxorubicin and Doxil® 
Doxorubicin, also known as adriamicyn, is a potent drug from the anthracycline 
family first discovered in 1969 by Italian researchers [56] and extensively used in the 
treatment of several malignancies including breast, lung, gastric, ovarian and thyroid 
cancer, as well as non-Hodgkin’s and Hodgkin’s lymphoma, sarcoma, and leukemia 
(Figure 2.4).  
The main mechanism of action of doxorubicin is DNA damage (i.e. single and 
double strand breaks) mediated by the enzyme topoisomerase II. In the presence of 
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ATP, topoisomerase II catalyzes a number of topological isomerization reactions by 
binding to the DNA strands and causing transient DNA breaks. This intermediate breaks 
allow the DNA to be untangled for replication and transcription and at the end of these 
processes the DNA backbone is resealed from topoisomerase II and the strands are 
linked back together. Doxorubicin affects the breakage-reunion reaction by stabilizing 
the complex formed by topoisomerase II and DNA, interfering with DNA replication and 
RNA synthesis [57].  
The non-specific nature of its mechanism of action causes doxorubicin to be very 
toxic not only for cancer cells but also for healthy cells, especially those of rapid 
duplication. Therefore, doxorubicin treatment is associated with several side effects, 
being cardiotoxicity the most serious. Doxorubicin cardiotoxicity manifests as 
progressive myocardial damage that may lead to congestive heart failure. The risk of 
developing cardiotoxicity increased with the accumulative dose, an estimate 5% 
patients develop congestive heart failure at a cumulative dose of 400 mg/m2, rising to 
16% at a dose of 500 mg/m2, 26% at a dose of 550 mg/m2, and 48% at a dose of 700 
mg/m2. Cardiotoxicity limits the utility of doxorubicin in the clinic since lower doses have 
to be administered or doxorubicin has to be replace for alternative and potentially less 
effective agents [58]. Myelosuppression is another dose limiting side effect of 
doxorubicin. This bone marrow effects may  result  in increased  incidence  of  
infections,  hindered  healing  and  gingival  bleeding.  Other common side effects of 
doxorubicin are acute nausea and vomiting, stomatitis, gastrointestinal disturbances, 
liver toxicity and alopecia [59]. The broad clinical use of doxorubicin and its dose limiting 









After extensive research and optimization, in 1995 the FDA approved the first 
nanomedicine known as Doxil®. Doxil® is a liposomal formulation of doxorubicin 
designed to evade RES internalization by the incorporation of PEGylated 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine (PEG2000-DSPE). Doxil® was initially approved for 
the treatment of Kaposi’s sarcoma, a common malignancy in patients living with 
HIV/AIDS and subsequently its indications expanded to recurrent ovarian cancer, 
metastatic breast cancer and multiple myeloma.   
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In humans, Doxil® is much better tolerated than conventional doxorubicin, being 
its major benefits a reduction in the incidence of serious side effects, including cardiac 
toxicity, and an improvement in patience quality of life.  Nonetheless, Doxil® displays 
unique side effects such as mucositis and severe desquamating dermatitis (“foot and 
hand syndrome”) that limit the doses that can be administered to patients. As a 
consequence, Doxil® does not displayed better efficacy when compared to the standard 
of care treatment [60, 61]. Next-generation doxorubicin nanomedicines could met the 
increased efficacy expectation by addressing the issues associated with Doxil® toxicity, 
including skin accumulation and uncontrolled drug release in the skin so higher doses 
can be administered. On the other hand, manufacturing issues have cause shortage of 
Doxil® in recent years [62], therefore, nanomedicines that can be fabricated by simple 















[1] Council NSaT. National nanotechnology initiative strategic plan 2016. 
[2] Freitas RA. What is nanomedicine? Nanomedicine: Nanotechnology, Biology and 
Medicine. 2005;1:2-9. 
[3] Ventola CL. The Nanomedicine Revolution: Part 2: Current and Future Clinical 
Applications. Pharmacy and Therapeutics. 2012;37:582-91. 
[4] FDA. Considering whether an FDA-regulated product involves the application of 
nanotechnology-Guidance for industry. 2014. 
[5] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based 
Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. 
Pharmaceutical research. 2016;33:2373-87. 
[6] Mukherjee S. The emperor of all maladies: a biography of cancer. New York: 
Scribner 2010. 
[7] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an 
emerging platform for cancer therapy. Nature nanotechnology. 2007;2:751-60. 
[8] Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and 
strategies in anti-cancer nanomedicine development: An industry perspective. 
Advanced Drug Delivery Reviews. 
[9] Park K. Questions on the role of the EPR effect in tumor targeting. Journal of 
controlled release : official journal of the Controlled Release Society. 2013;172:391. 
[10] Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution 
and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR 
effect and image-guided drug delivery. Journal of controlled release : official journal of 
the Controlled Release Society. 2013;172:12-21. 
[11] Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of 
nanoparticle delivery to tumours. Nature Reviews Materials. 2016;1:16014. 
[12] Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, 
consequences, and strategies to normalize. Journal of cellular biochemistry. 
2007;101:937-49. 
[13] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor 
agent smancs. Cancer research. 1986;46:6387-92. 
[14] Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. 
Journal of controlled release : official journal of the Controlled Release Society. 
2011;153:198-205. 
[15] Luque-Michel E, Imbuluzqueta E, Sebastián V, Blanco-Prieto MJ. Clinical advances 
of nanocarrier-based cancer therapy and diagnostics. Expert Opinion on Drug Delivery. 
2017;14:75-92. 
[16] Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal Clearance of 
Nanoparticles. Nature biotechnology. 2007;25:1165-70. 
[17] Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling 
biodistribution and tumor uptake of GM1-containing liposomes. Biochimica et 
Biophysica Acta (BBA) - Biomembranes. 1992;1104:95-101. 
33	
	
[18] Tang L, Yang X, Yin Q, Cai K, Wang H, Chaudhury I, et al. Investigating the optimal 
size of anticancer nanomedicine. Proceedings of the National Academy of Sciences. 
2014;111:15344-9. 
[19] CabralH, MatsumotoY, MizunoK, ChenQ, MurakamiM, KimuraM, et al. 
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends 
on size. Nat Nano. 2011;6:815-23. 
[20] Toy R, Peiris PM, Ghaghada KB, Karathanasis E. Shaping cancer nanomedicine: 
the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine 
(London, England). 2014;9:121-34. 
[21] Nicolai T, Colombani O, Chassenieux C. Dynamic polymeric micelles versus frozen 
nanoparticles formed by block copolymers. Soft Matter. 2010;6:3111-8. 
[22] Letchford K, Burt H. A review of the formation and classification of amphiphilic block 
copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and 
polymersomes. European Journal of Pharmaceutics and Biopharmaceutics. 
2007;65:259-69. 
[23] Lee JS, Feijen J. Polymersomes for drug delivery: Design, formation and 
characterization. Journal of Controlled Release. 2012;161:473-83. 
[24] Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles 
in anticancer therapy: targeting, imaging and triggered release. Pharmaceutical 
research. 2010;27:2569-89. 
[25] Biswas S, Kumari P, Lakhani PM, Ghosh B. Recent advances in polymeric micelles 
for anti-cancer drug delivery. European journal of pharmaceutical sciences : official 
journal of the European Federation for Pharmaceutical Sciences. 2016;83:184-202. 
[26] Ercole F, Whittaker MR, Quinn JF, Davis TP. Cholesterol Modified Self-Assemblies 
and Their Application to Nanomedicine. Biomacromolecules. 2015;16:1886-914. 
[27] Yu Y, He Y, Xu B, He Z, Zhang Y, Chen Y, et al. Self-assembled methoxy 
poly(ethylene glycol)-cholesterol micelles for hydrophobic drug delivery. Journal of 
pharmaceutical sciences. 2013;102:1054-62. 
[28] Taymouri S, Varshosaz J, Hassanzadeh F, Javanmard SH, Dana N. Optimisation 
of processing variables effective on self-assembly of folate targeted Synpronic-based 
micelles for docetaxel delivery in melanoma cells.  IET Nanobiotechnology: Institution of 
Engineering and Technology; 2015. p. 306-13. 
[29] Yusa S. Self-Assembly of Cholesterol-Containing Water-Soluble Polymers. 
International Journal of Polymer Science. 2012;2012. 
[30] Lee AL, Venkataraman S, Sirat SB, Gao S, Hedrick JL, Yang YY. The use of 
cholesterol-containing biodegradable block copolymers to exploit hydrophobic 
interactions for the delivery of anticancer drugs. Biomaterials. 2012;33:1921-8. 
[31] Muddineti OS, Vanaparthi A, Rompicharla SVK, Kumari P, Ghosh B, Biswas S. 
Cholesterol and vitamin E-conjugated PEGylated polymeric micelles for efficient 
delivery and enhanced anticancer activity of curcumin: evaluation in 2D monolayers and 
3D spheroids. Artificial Cells, Nanomedicine, and Biotechnology. 2018:1-14. 
[32] Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. MPEO-PLA 
nanoparticles: effect of MPEO content on some of their surface properties. Journal of 
biomedical materials research. 1999;44:109-15. 
34	
	
[33] Rolland A, Verge RL, Collet B, Toujas L. Blood clearance and organ distribution of 
intravenously administered polymethacrylic nanoparticles in mice. Journal of 
pharmaceutical sciences. 1989;78:481-4. 
[34] Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving 
nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews. 2016;99, 
Part A:28-51. 
[35] Vonarbourg A, Passirani C, Saulnier P, Benoit J-P. Parameters influencing the 
stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27:4356-73. 
[36] Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug 
delivery: pros and cons as well as potential alternatives. Angewandte Chemie 
(International ed in English). 2010;49:6288-308. 
[37] Yu Y, Sun H, Cheng C. Chapter 8 - Brush polymer-based nanostructures for drug 
delivery. In: Andronescu E, Grumezescu AM, editors. Nanostructures for Drug Delivery: 
Elsevier; 2017. p. 271-98. 
[38] Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-
control parameters. Progress in Polymer Science. 2011;36:887-913. 
[39] FDA. Q3C-Guidance for Industry. 2018. 
[40] Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, Akhoundi 
Kharanaghi E, Mohammadnejad Arough J, et al. Overview of preparation methods of 
polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A 
comprehensive review. International Journal of Polymeric Materials and Polymeric 
Biomaterials. 2018;67:383-400. 
[41] Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug 
Deliv. 2006;3:139-62. 
[42] Tirelli N. (Bio)Responsive nanoparticles. Current Opinion in Colloid & Interface 
Science. 2006;11:210-6. 
[43] Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL, Yamada K, et al. 
Noninvasive Imaging of Tumor Redox Status and Its Modification by Tissue Glutathione 
Levels. Cancer research. 2002;62:307-12. 
[44] Wong DY-K, Hsiao Y-L, Poon C-K, Kwan P-C, Chao S-Y, Chou S-T, et al. 
Glutathione concentration in oral cancer tissues. Cancer letters. 1994;81:111-6. 
[45] Davis SR, Quinlivan EP, Stacpoole PW, Gregory IIIJF. Plasma Glutathione and 
Cystathionine Concentrations Are Elevated but Cysteine Flux Is Unchanged by Dietary 
Vitamin B-6 Restriction in Young Men and Women. The Journal of nutrition. 
2006;136:373-8. 
[46] Li Y, Xiao K, Luo J, Xiao W, Lee JS, Gonik AM, et al. Well-defined, reversible 
disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials. 
2011;32:6633-45. 
[47] Koo AN, Min KH, Lee HJ, Lee SU, Kim K, Kwon IC, et al. Tumor accumulation and 
antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific 
redox-responsive cross-links. Biomaterials. 2012;33:1489-99. 
[48] Ren G, Liu D, Guo W, Wang M, Wu C, Guo M, et al. Docetaxel prodrug liposomes 




[49] Xiao D, Hu JJ, Zhu JY, Wang SB, Zhuo RX, Zhang XZ. A redox-responsive 
mesoporous silica nanoparticle with a therapeutic peptide shell for tumor targeting 
synergistic therapy. Nanoscale. 2016;8:16702-9. 
[50] Kim JO, Sahay G, Kabanov AV, Bronich TK. Polymeric micelles with ionic cores 
containing biodegradable cross-links for delivery of chemotherapeutic agents. 
Biomacromolecules. 2010;11:919-26. 
[51] Li J, Huo M, Wang J, Zhou J, Mohammad JM, Zhang Y, et al. Redox-sensitive 
micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates 
for targeted intracellular delivery of paclitaxel. Biomaterials. 2012;33:2310-20. 
[52] Lu D, Tawfik O, Pantazis C, Hobart W, Chapman J, Iczkowski K. Altered 
Expression of CD44 and Variant Isoforms in Human Adenocarcinoma of the Endocervix 
during Progression. Gynecologic oncology. 1999;75:84-90. 
[53] Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical Translation of Nanomedicine. 
Chemical Reviews. 2015;115:11147-90. 
[54] Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, et al. (64)Cu-MM-302 
Positron Emission Tomography Quantifies Variability of Enhanced Permeability and 
Retention of Nanoparticles in Relation to Treatment Response in Patients with 
Metastatic Breast Cancer. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2017;23:4190-202. 
[55] Tsujikawa T, Asahi S, Oh M, Sato Y, Narita N, Makino A, et al. Assessment of the 
Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET. PloS one. 
2016;11:e0155635. 
[56] Arcamone F, Franceschi G, Penco S, Selva A. Adriamycin (14-
hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron letters. 1969:1007-10. 
[57] Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA 
damage mediated by mammalian DNA topoisomerase II. Science (New York, NY). 
1984;226:466-8. 
[58] Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with 
doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-79. 
[59] Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. 
Doxorubicin: the good, the bad and the ugly effect. Current medicinal chemistry. 
2009;16:3267-85. 
[60] Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. 
Journal of Controlled Release. 2012;160:117-34. 
[61] Solomon R, Gabizon AA. Clinical Pharmacology of Liposomal Anthracyclines: 
Focus on Pegylated Liposomal Doxorubicin. Clinical Lymphoma and Myeloma. 
2008;8:21-32. 
[62] Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, et al. Is it 
equivalent? Evaluation of the clinical activity of single agent Lipodox(R) compared to 
single agent Doxil® in ovarian cancer treatment. Journal of oncology pharmacy practice 








Chapter 3.  
Reduced In Vivo Toxicity of Doxorubicin by Encapsulation in Cholesterol-
























Our laboratory previously reported the development of an amphiphilic brush-like 
block copolymer composed of polynorbornene-cholesterol/polyethylene glycol 
(P(NBCh9-b-NBPEG)) that self-assembles in aqueous media to form long circulating 
nanostructures capable of encapsulating doxorubicin (DOX-NPs). Biodistribution studies 
showed that this formulation preferentially accumulates in tumor tissue with markedly 
reduced accumulation in the heart and other major organs. The aim of this chapter was 
to evaluate the in vivo efficacy and toxicity of DOX-NPs in a mouse xenograft human 
tumor model and compare its effects with the hydrochloride non-encapsulated form of 
the drug (DOX-HCl). DOX-NPs significantly reduced the growth of tumors without 
inducing any apparent toxicity. Conversely, mice treated with DOX-HCl exhibited 
significant weight loss, early toxic cardiomyopathy, acute toxic hepatopathy, reduced 
hematopoiesis and fatal toxicity. The improved safety profile of the polymeric DOX-NPs 
can be explained by the low circulating concentration of non-nanoparticle-associated 
drug as well as the reduced accumulation of DOX in off-target organs.  
 
3.2 . Introduction 
Despite its many indications in clinical oncology, the use of doxorubicin (DOX) is 
limited by potentially fatal and irreversible cardiotoxicity [1, 2]. Liposomal formulations 
on the market (e, g., Doxil® and Myocet®) have partially addressed this issue [3-5]. 
However, different side effects from what is observed with the hydrochloride free form of 
DOX such as hand-foot syndrome, and complement activation-related pseudo-allergy 
may require dose reduction or treatment discontinuation depending on the severity of 
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the symptoms [6-8]. Liposome-encapsulated DOX can also exert toxic effects on the 
liver macrophage population with impaired phagocytic function and reduced ability of 
colloid particle clearance [9]. Furthermore, the complexity of its manufacturing process, 
especially in the case of Doxil®, increases the risk of critical drug shortage [10].  
Polymeric self-assembled nanoparticles from amphiphilic block copolymers offer 
several advantages over other nanocarriers for drug delivery such as tunable particle 
size, high loading capacity of hydrophobic drugs, flexible chemistry, and colloidal 
stability [11]. Recently, polymeric nanoparticles from brush amphiphilic copolymers are 
gaining attention as delivery systems because of their low critical aggregation 
concentrations (CAC) and subsequent high stability upon dilution [12]. Brush type 
architecture with biocompatible side chain units can be envisioned to obtain amphiphilic 
brush block copolymers capable of forming stable biocompatible nanoparticles which 
can encapsulate hydrophobic DOX. Delivery of DOX using polymeric self-assembled 
nanoparticles has been extensively investigated in the past, providing evidence of 
improved biodistribution and reduced tumor growth [13-15]. However, reports about the 
safety of the drug-carrier systems and their organ specific effects are scarce since most 
of the reports either do not include in vivo toxicity studies or evaluate reduction in body 
weight as the only sign of toxicity.  
Our laboratory previously reported the development of self-assembled 
nanoparticles formed from a cholesterol-based brush copolymer capable of 
encapsulating hydrophobic DOX. Besides displaying excellent stability, prolonged in 
vivo circulation and high tumor accumulation, this nanoparticle formulation (DOX-NPs) 
39	
	
significantly reduced DOX accumulation in the heart, liver and spleen of tumor-bearing 
mice [16].  
To further advance the development process and fully evaluate this drug delivery 
system we studied drug release in biorelevant media, assessed the biocompatibility of 
the nanocarrier and evaluated the efficacy and toxicity of this nanoparticle formulation in 
a mouse xenograft tumor model in comparison with the hydrochloride non-encapsulated 
form of the drug (DOX-HCl).  
 
3.3. Methods and materials 
 
3.3.1. Materials 
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc. 
(Waltham, MA, USA). Triethylamine (TEA) and dimethylformamide (DMF) were 
purchased from Fisher Scientific (Boston, MA, USA). Penicillin−streptomycin, 0.25% 
(w/v) trypsin 0.03% (w/v)-EDTA solution, RPMI 1640, and DMEM were purchased from 
American Type Culture Collection (Rockville, MD, USA). The human lung cancer cell 
line (A549) was purchased from the American Type Culture Collection (Manassas, VA, 
USA). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, GA, 
USA). Human plasma and plasma from BALB/c mice were purchased from Innovative 
Research (Novi, MI, USA). Spectra/Pro dialysis membranes were obtained from 
Spectrum Laboratories (Rancho Dominguez, CA, USA). Centrifugal filters were 
purchased from Millipore (Darmstadt, Germany). Esterase from porcine liver (3.2 M 
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(NH4)2SO4, 28.1 mg of protein/ml, 218 units/mg of protein) was obtained from Sigma-
Aldrich (St Louis, MO, USA). All chemicals were analytical or HPLC grade.  
 
3.3.2. Synthesis and Purification of P(NBCh9-b-NBPEG) 
Synthesis of norbornene functionalized monomers, 5-{9-
(cholesteryloxycarbonyl)-nonyloxycarbonyl}-bicyclo[2.2.1]hept-2-ene (NBCh9) and 
methoxy polyethylene glycol (MPEG) (Mn = 2 Kg/mol) functionalized norbornene 
(NBPEG) was previously reported [17] [18]. All brush-like block copolymers were 
synthesized using ring opening metathesis polymerization (ROMP), the synthesis and 
characterization details are described in a previous publication [18]  
 
3.3.3. Preparation and characterization of blank nanoparticles and DOX-NPs. 
The preparation and characterization of blank and DOX-containing nanoparticles 
was described in a previous publication [16]. Briefly, blank nanoparticles were prepared 
by dissolving the polymer in DMF and subsequent dialysis of the solution against 
ultrapure water for 48 hours. For the preparation of DOX-NPs, hydrophobic DOX was 
obtained by deprotonation of DOX-HCl solubilized in DMF with TEA. The reaction was 
allowed to proceed overnight at room temperature. Later on, deprotonated DOX was 
added to the polymer solution in DMF, at a mass ratio of 1:3 (drug: polymer), and the 
mixture was stirred for 1 hour at room temperature. Finally, the solution was dialyzed for 
48-72 hours to allow the polymeric nanoparticles to form. The nanoparticles were 
purified by centrifugation at 8000 rpm for 10 min, followed by filtration through 0.45 μm 
filter. To eliminate non-nanoparticle-associated soluble DOX, the nanoparticles were 
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ultrafiltered (MWCO 10 kDa) with centrifugation at 8000 rpm for 10 minutes. 
Nanoparticle suspensions were kept at 4°C until use or lyophilized and stored at 4°C. 
The average particle size and size distribution were measured using a nanoparticle 
tracking analysis instrument (Nanosight, Malvern, UK). The amount of DOX-loaded into 
nanoparticles was determined by interpolation in a standard curve of concentration vs 
absorbance at 480 nm using an UV−Vis spectrophotometer (Shimadzu, Japan). 
 
3.3.4. In vitro release of DOX from nanoparticles in biorelevant media 
To rule out the possibility of burst and esterase-mediated release of DOX in 
plasma, DOX-NPs were incubated with media containing various levels of esterase 
activity. PBS buffer (pH 7.4), 10% human plasma, 10% mouse plasma, 10% A549 
cancer cells homogenate and carboxylesterase equivalent to 10% mouse plasma (1.86 
units/ml) were evaluated for their ability to release DOX from the nanoparticles, 
presumably due to cleavage of ester bonds in the polymer structure. Nanoparticles 
equivalent to 20 µg/ml DOX were incubated with the release media at 37°C with 
agitation at 100 rpm for 24 hours. In all cases, the release media contained 0.1% (w/v) 
Tween-80. Ultrafiltration using a 10 kDa filter and centrifugation at 8000 rpm and 37°C 
for 1 hour was used to separate DOX released from the nanoparticles. DOX in the 
filtrate was quantified by fluorescence spectroscopy at 480/560 excitation/emission. 
In vitro drug release over time was studied by incubating nanoparticles 
equivalent to 10 µg/ml of DOX with PBS (pH 7.4) or PBS containing carboxylesterase. 
At each time point (4, 24, 48, 72 and 144 hours), 1 ml aliquots were removed for 
quantification of DOX released from the nanoparticles and 1 ml of fresh media was 
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added to keep a constant volume of 20 ml. In all cases, release media contained 0.1% 
(w/v) Tween-80. Ultrafiltration using a 10 kDa filter and centrifugation at 8000 rpm and 
37°C for 1 hour was used to separate released DOX from the nanoparticles. DOX in the 
filtrate was quantified by fluorescence spectroscopy at 480/560 excitation/emission. 
 
3.3.5 Quantification of non-nanoparticle-associated DOX and DOX-NPs in plasma 
of mice treated with DOX-NPs 
SCID mice at 6-8 weeks of age received a single dose of DOX-NPs or DOX-HCl 
equivalent to 5 mg/kg of DOX via tail vein injection. At 0.25 and 2 hours post injection, 
blood was collected by cardiac puncture. Plasma was separated by centrifugation (3000 
rpm, 10 min, and 4°C). In plasma from mice injected with DOX-NPs, ultrafiltration using 
a 50 kDa filter and centrifugation at 8000 rpm and 5°C for 1 hour was used to separate 
non-nanoparticle-associated DOX from the nanoparticles. Non-nanoparticle-associated 
DOX was directly quantified by fluorescence as described above. DOX-NPs and free 
DOX-HCl were quantified by fluorescence after extraction from plasma with acidic 
isopropanol as described in Shi et al [19]. 
 
3.3.6. Evaluation of the effect of blank NPs on tumor bearing SCID mice  
All animal studies were performed according to an approved protocol by 
Institutional Animal Care and Use Committee (IACUC) at the University of Connecticut.  
To evaluate in vivo effects of i.v administration of blank nanoparticles without drug, 10 
SCID mice at 6-8 weeks of age were inoculated subcutaneously with 2x106 A549 cells. 
Two weeks after tumor implantation, mice were randomly divided into two groups (n=5). 
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One group received 6 mg/kg blank nanoparticles twice per week, while the control 
group received saline. Tumor size and body weight, as an indicator of systemic toxicity, 
were monitored three times per week. Tumor volume was calculated using the following 
equation: tumor volume (mm3) = width2 x length/2. Treatment was administered for 6 
weeks, followed by plasma and major organs collection for pathology and biochemical 
analysis. Organs were fixed in 10% buffered formalin and	embedded in paraffin. Four 
micron sections were sliced and stained using Hematoxylin & Eosin staining (H&E). 
Histological changes in heart, liver and spleen were determined by pathology analysis.  
 
3.3.7. Anti-tumor efficacy and toxicity of DOX-NPs and free DOX-HCl 
The antitumor activity of DOX-HCl and DOX-NPs was evaluated in tumor-bearing 
SCID mice inoculated subcutaneously in the right flank with 2 × 106 A549 cells. When 
the tumors grew to an average size of 30 mm3, mice were randomly divided into four 
treatment groups containing four mice each (n=4): 5 mg/kg DOX-NPs, 5 mg/kg DOX-
HCl, 1 mg/kg DOX-HCl and saline. Mice treated with 5 mg/kg DOX-NPs and saline were 
injected intravenously once a week via the tail vein.  Due to high toxicity at the site of 
injection that prevents frequent administration of DOX-HCl via tail vein injection, mice 
receiving 5 and 1 mg/kg DOX-HCl were injected intraperitoneally once a week. Previous 
studies have reported similar plasma and liver concentrations of DOX after i.v and i.p 
administration in nude mice even though concentrations in other organs like heart and 
muscle may be affected by the route of administration [20]. Tumor size and body weight 
were monitored three times per week. After 8 weeks of treatment, mice were sacrificed 
and plasma and major organs were collected for pathology and biochemical analysis.  
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3.3.8. Alanine aminotransferase (ALT) assay 
ALT plasma levels were determined as a biomarker for liver damage in mice after 
8 weeks of treatment with 5 mg/kg DOX-NPs, 1 mg/kg DOX-HCl or saline once per 
week. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc., Waltham, MA) 
was used to determine ALT activity. Briefly, 100 μl of reagent was added to 10 μl serum 
or plasma samples, and absorbance was measured spectrophotometrically at 340 nm 
using a Bio-Tek Power Wave X Spectrophotometer. ALT activity (U/l) was determined 
using the molar extinction coefficient of NADH (6.3 mM−1cm−1). 
 
3.3.9. Cardiac troponin assay 
The mouse cardiac troponin-I ultra-sensitive ELISA kit (Life Diagnostics, PA, 
USA) was used to quantify cardiac troponin levels in plasma samples from mice treated 
with 5 mg/kg DOX-NPs, 1 mg/kg DOX-HCl or saline once per week for 8 weeks. Mouse 
plasma was separated from blood collected through submandibular bleeding. 
 
3.3.10. Statistical analysis 
One-way ANOVA or the Kruskal-Wallis tests were used to establish statistical 
differences among groups. Tukey's or Dunn´s Multiple Comparison tests were 
performed to compare each treatment group with the other groups, according to the 
parametric or non-parametric distribution of data. Survival curves were generated using 
the Gelhan Wilcoxon method. Analyses were performed with GraphPad Prism 6 




3.4. Results and discussion 
 
3.4.1. Nanoparticle characterization 
The characterization parameters for the polymer, blank nanoparticles and DOX-
NPs are summarized in Table 3.1.  
 






Wt. Fraction (%) 








GPC (PDI) NBCh9 NBMPEG 
(PNBCh9)-b-
(PNBMPEG) 
162 (1.3) 7.45 92.54 - 83.7 ± 1.1 - - 
(PNBCh9)-b-
(PNBMPEG) 
162 (1.3) 7.45 92.54 1:3 94.5 ± 2.0 14.5 58.0 
 
aMolecular weight was determined by GPC relative to PMMA standards with dimethyl 
acetamide (DMAc) as eluent.  
bWeight percent of monomer was determined by 1H NMR integration of peaks at 4.6 for 
cholesterol and 3.35 for PEG side chains. 
cDOX:polymer feed weight ratio  
dDLC, drug loading content.  
eEE, encapsulation efficiency. 
 
3.4.2. In vitro release of DOX from nanoparticles in biorelevant media 
An initial concern about the in vivo performance of DOX-NPs in the mouse model 
was the possibility of uncontrolled drug release trigged by esterases. Preceding works 
have reported rapid release of drugs from nanoparticles prepared with ester containing 
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compounds in mouse plasma due to its high esterase activity [21-23]. Both PEG and 
cholesterol are bound to the polynorbornene backbone through ester bonds. Therefore 
media with reported esterase activity were included in the study to rule out the 
possibility of uncontrolled release triggered by esterases as highlighted by previous 
publications [21, 22]. It is known that mouse plasma and cancer cells exhibit relatively 
high esterase activity compared to human plasma and PBS (22).  After 24 hours of 
incubation, an overall increase in the release of DOX was observed in the presence of 
different media when compared with PBS alone (cumulative release = 6%).  Human 
plasma produced a mild increase (11.2%) while carboxylesterases (14.5%), A549 cell 
lysate (20%) and mouse plasma (20.6%) exhibited a more pronounced effect (Figure 
3.1A). To further investigate the effect of esterases on the release of DOX from the 
nanoparticles, the in vitro release in the presence of carboxylesterases was studied 
over time. At each time point, drug release was higher in the media containing 
carboxylesterases than in media without enzymes (Figure 3.1B), reaching a maximum 
release of 16% after 48 hours while the highest release observed for PBS was 10.8% 
after 144 hours.  The limited extent of the release in the presence of esterases suggests 






Figure 3.1. Release of DOX from DOX-NPs at 37°C. A) Media with different levels of 
esterase activity. One way ANOVA test, *p < 0.05, ***p < 0.001 ****p < 0.0001. B) Media 
with carboxylesterases. Data are based on 3 independent experiments and are 
expressed as means ± SD.  
 
3.4.3. Non-nanoparticle-associated DOX in circulation 
To estimate the amount of drug in the non-nanoparticle-associated form after the 
administration of DOX-NPs to mice, we separated the nanoparticles by ultrafiltration and 
quantified the non-nanoparticle-associated drug in the filtrate. At two time points after 
injection, 0.25 and 2 hours, the encapsulated form made the majority of the total drug in 
circulation, 92% and 88.4% respectively (Figure 3.2). The concentrations of non-
nanoparticle-associated DOX after the administration of DOX-NPs, at 0.25 and 2 hours 
were 1.9 µg/ml and 2.1 µg/ml respectively. As previously reported [16], the 
concentration of DOX-HCl rapidly decreased from 25 µg/ml at 0.25 hours to 5 µg/ml at 2 
hours. The concentration of non-nanoparticle-associated DOX in plasma was 13.2 and 
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2.4 times lower than the concentration of free drug when administering DOX-HCl at 0.25 
h and 2 h time points respectively (Figure 3.2). These results suggest that release of 
DOX in circulation is minimal, which ensures that little drug reaches tissues with healthy 




Figure 3.2. DOX concentrations in plasma expressed in the form of DOX-NPs and Non-
nanoparticle-associated DOX after the administration of 5 mg/kg DOX-NPs, as well as 
DOX-HCl after the administration of 5 mg/kg DOX-HCl (n = 3; mean ± SD). One way 
ANOVA test, **** p < 0.0001. 
 
3.4.4. Evaluation of the effect of blank NPs on tumor bearing SCID mice 
To evaluate the biocompatibility of P(NBCh9-b-NBPEG) nanoparticles, we 
studied the effects of blank nanoparticles on tumor bearing SCID mice by treating them 
with a dose of 6 mg/kg polymer mass, twice a week for 6 weeks. There were no 
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significant differences in the body weight or tumor growth of mice treated with blank 
nanoparticles when compared to the control group (Figure 3.3). No lesions were found 
in the hearts, livers or spleens of mice treated with blank nanoparticles (Figure 3.4). No 
significant increase in ALT plasma levels were detected in mice treated with blank 
nanoparticles compared to mice treated with saline (24.1 ± 0.2 U/l vs 23.4 ± 6.1 U/l, 
respectively), being the average base line value for healthy mice 15.3 ± 2.0 U/l. 
Potential effects in the liver where a particular concern since nanoparticles in general 
tend to accumulate in this organ. However, results showed that the administration of 




Figure 3.3. Effect of the administration of 6 mg/kg blank NPs, twice per week on tumor-
bearing SCID mice. A) Body weight. B) Tumor growth ratio (Volume/Initial Volume), (n = 




There are very few reports of polynorbornenes intended for biomedical 
applications and none of those studies evaluated their effects in vivo [24-26]. This study 
constitutes the first report of the in vivo safety evaluation of a polymer containing a 





Figure 3.4. Histology of tissues from tumor bearing SCID mice treated with 6 mg/kg 






3.4.5. Anti-tumor efficacy and toxicity of DOX-NPs and DOX-HCl   
DOX-NPs significantly reduced the growth of tumors after 40 days of treatment. 
Tumor growth was also inhibited by 1 mg/kg DOX-HCl but the inhibition reached 
statistical significance only at day 54 (Figure 3.5). The effect of 5 mg/kg DOX-HCl could 
not be assessed because mice in this group died after the second dose, presumably 




Figure 3.5. Effect of the administration of 5 mg/kg DOX-NPs, once per week, on tumor 
growth. Comparison of the tumor inhibition effect of DOX-NPs versus DOX-HCl and 
saline. Data are shown as tumor growth ratio relative to the initial tumor size (V/Vo), (n = 
4; mean ± SD).*Statistical significant difference between DOX-NPs and saline, one way 
ANOVA test, p < 0.05. ** Statistical significant difference between DOX-NPs and saline 
p < 0.01.#Statistical significant difference between DOX-HCl and saline, one way 
ANOVA test, p < 0.05. 
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One can attribute the good efficacy results of DOX-NPs to three major factors: 1) 
extended systemic circulation time, 2) extravasation and tumor accumulation and 3) 
interaction with the target cells [27]. The size of these DOX-NPs (94.5 nm) prevents 
them from diffusing through the endothelial layer of normal blood vessels or being 
excreted by renal filtration. The external PEG block of the nanoparticles reduces their 
internalization by RES cells therefore prolonging their circulation in the blood, as 
previously reported [16]. This likely increases their chances of interacting with tumor 
tissues. The small particle size also allows them to cross the leaky tumor vasculature 
and accumulate in tumor tissues by the enhanced permeability and retention (EPR) 
effect. Finally, the fact that drug release increased when incubating with A549 cell lysate 
and the evidence of cell internalization (16) suggest that once inside the cells, DOX can 
be slowly released from the nanoparticles by enzymatic activity which also contributes 
to the observed anti-tumor effect. 
DOX-NPs did not induce weight loss in treated mice while 1 mg/kg DOX-HCl 
induced an average weight loss of 26.1% by the end of the study. Mice treated with 5 
mg/kg DOX-HCl showed a 28.1% average weight lost after receiving just two doses 
(Figure 3.6A). DOX-NPs significantly increased the survival rate of tumor bearing mice 
compared to DOX-HCl. All the mice treated with DOX-NPs survived the full treatment 
course without showing signs of systemic toxicity (Figure 3.6B). On the other hand, 
100% of the mice treated with 5 mg/kg DOX-HCl died two weeks after the treatment 
started while 100% of the mice treated with 1 mg/kg DOX-HCl died by day 54. Seventy 
five percent of the mice treated with saline survived the full treatment course (Figure 





Figure 3.6. Safety of the administration of 5 mg/kg DOX-NPs on tumor-bearing mice, 
once per week. Data are expressed as mean (n = 4) ± SD. A) Body weight. 
****Statistically significant differences between DOX-HCl 5 mg/kg and saline, One-way 
ANOVA test, p < 0.0001. #Statistically significant differences between DOX-HCl 1 mg/kg 
and saline, ANOVA test, p < 0.05. B) Survival. *Statistically significant differences 
between DOX-HCl 5 mg/kg and saline, Gelhan-Wilcoxon test, p < 0.05.  
 
Regarding the effect of the treatments in organs that are common targets of DOX 
toxicity, mice treated with 1 mg/kg and 5 mg/kg DOX-HCl showed signs of early toxic 
cardiomyopathy characterized by cardiac muscle cell striation disruption and granularity 
with some eosinophilic and vacuolated sarcoplasm and pyknotic endothelial cell nuclei 
in the capillary network. Signs of acute toxic hepatopathy such as hypercellularity due to 
an increased number of neutrophils as well as early signs of necrosis, including nuclear 
fading (karyolysis), nuclear shrinkage (pyknosis) and fragmentation (karyorrhexys), and 
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hemosiderin accumulation in Kupffer cells, were observed in the livers of mice treated 
with free DOX. Reduced hematopoiesis, lymphoid germinal center absence and spleen 
necrosis were observed as well (Figure 3.7). Remarkably, no significant lesions were 
found in the livers, hearts, spleens or kidneys of any of the mice treated with DOX-NPs. 




Figure 3.7. Effect of treatment in the tissues of tumor-bearing SCID mice. Heart) Early 
signs of necrosis in cardiac tissue are highlighted with red arrows: cardiac muscle cell 
striation disruption and granularity and sarcoplasmic vacuolations. Liver) Early signs of 
necrosis in hepatic tissue are highlighted with red arrows: nuclear fading (karyolysis), 
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nuclear shrinkage (pyknosis) and fragmentation (karyorrhexys). Spleen) Lymphoid 
germinal center absence is highlighted with red arrows. 
 
Plasma ALT levels were measured as a biomarker for liver damage. Tumor-
bearing mice treated with 1 mg/kg DOX-HCl showed a significant increase in ALT 
values (146.8 ± 4.9 U/l) when compared to healthy mice (15.3 ± 2.0 U/l) and tumor 
bearing mice treated with saline (23.4 ± 6.0 U/l). No significant alterations of ALT 
plasma levels were found in the DOX-NPs treated group (19.5 ± 4.4 U/l) after 8 weeks 
of treatment (Figure 3.8A). Cardiac troponin I quantification suggests that the levels of 
this heart damage marker increased in mice treated with DOX-HCl 1 mg/kg once a 
week for 8 weeks and also with single dose administration of 20 mg/kg DOX-HCl 
(Figure 3.8B). No alterations were found in mice treated with DOX-NPS in comparison 







Figure 3.8 Plasma ALT and troponin levels from mice treated with saline, DOX-HCl or 
DOX-NPs. A) ALT is expressed as international units (U) per liter (n = 4; mean ± SD). 
The average detected ALT level of healthy controls was 15.3 U/l. ***Statistically 
significant differences between DOX-HCl and the other treatment groups, one way 
ANOVA test, p < 0.0005. B) Plasma troponin (n = 3; mean ± SD).  The average 
detected troponin level of the healthy controls was 0.081 ng/ml.  One way ANOVA test, 
*p < 0.05, **p < 0.01. 
 
Overall, compared to DOX-HCl, DOX-NPs exhibited a remarkable improvement 
in the safety profile. A close link exists between DOX accumulation in the heart, and the 
development of cardiomyopathy [28]. Bone marrow exposure to DOX also determines 
the severity of myelosuppression [29]. These striking differences can be largely explain 
by a) the notable change in the biodistribution of DOX, when administered as DOX-NPs, 
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reported in our previous study in which DOX accumulation in heart, liver and spleen was 
reduced 3.9, 6.5 and 4.6 times respectively [16] and b) the fact that most of the drug in 
circulation stays in the encapsulated form.  When administering the same dose of DOX-
HCl and DOX-NPs, the released DOX from DOX-NPs in blood was small compared to 
the amount of drug available to diffuse to the non-target organs after administration of 
DOX and cause toxic effects. Finally, even when some of the nanoparticles can 
accumulate in the reticulo-endothelial system, the slow release of the drug from the 
nanoparticles has a protective effect since only the non-nanoparticle-associated form 
can exert toxic effects when binding to cellular targets.   
Previous reports have pointed out the potential of polymer nanoparticles to limit 
DOX cardiac toxicity and myelosuppression [30-32]. We carefully evaluated the drug 
release profiles of our DOX-NPs both in vitro and in vivo, and assessed their tissue 
toxicity and anti-tumor efficacy. The results demonstrated the potential of the system to 
be a safer and more effective therapeutic agent to treat cancer. In addition, our DOX-
NPs provide the advantage of a simple preparation process that yields a relatively high 
drug loading (14-20%), making them advantageous based not only on their therapeutic 
effect, but also from the manufacturing perspective. 
 
3.5. Conclusion 
Self-assembled nanoparticles formed from cholesterol-based brush-like block 
copolymers proved to be safe for repeated administration. Treatment of tumor-bearing 
mice with DOX-NPs significantly reduced tumor growth without inducing DOX-HCl    
associated cardiac, liver toxicity or myelosuppression, providing 100% survival by the 
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end of the study. The improved safety profile of DOX-NPs can be explained by low 
release of DOX from the nanoparticles in plasma and subsequent low circulating 
concentration of non-nanoparticle-associated drug as well as the reduced accumulation 
of DOX in major organs like heart, liver and spleen. These findings support the use of 
P(NBCh9-b-NBPEG) nanoparticles as a delivery platform for hydrophobic anticancer 
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Chapter 4.   
Optimization of a Cholesterol-based Polymeric Nanoparticle Formulation for 
Bioresponsive Release of Doxorubicin in Tumor Cells: Impact of the Preparation 























Achieving selective drug release from nanoparticles in tumor tissues remains a 
challenge, which compromises the therapeutic effects of nanomedicines. In order to 
overcome this drawback, we designed a redox-sensitive cholesterol-based block 
copolymer (PC5MA-SS-PEO) that self-assembles into nanoparticles. A reducible 
disulfide bond was incorporated in the polymer structure to facilitate drug release once 
the bond is cleaved by intracellular glutathione (GSH) in tumor cells. The main objective 
of this chapter was to optimize the incorporation of doxorubicin (DOX) in redox-sensitive 
polymeric nanoparticles formed by PCMA-SS-PEO (DOX-SS-NPs) by understanding 
the effect of the method of preparation on critical nanoparticle attributes using a design 
of experiment (DOE) approach. Two methods of preparation were compared; the 
cosolvent removal method provided nanoparticles with small average particle size and 
narrow particle size distribution but low drug loading while the O/W emulsion method 
produced bigger nanoparticles with relatively high drug loading.  Significant influence of 
the method of preparation and formulation parameters on nanoparticle properties was 
observed and the best formulations were identified for further evaluation.  
 
4.2. Introduction 
Achieving rapid and selective drug release in tumor tissues is paramount to the 
development of efficacious nanomedicines. In that sense, several attempts to develop 
bioresponsive nanocarriers have been reported [1]. In this approach, the main goal is to 
produce delivery platforms that can quickly release their cargo once exposed to specific 
stimuli in the tumor microenvironment or inside cancer cells. Redox-sensitive 
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nanocarriers are of particular interest because of higher glutathione (GSH) 
concentrations in tumor tissues compared to normal tissues [2, 3] and plasma, thus 
enabling the inherent biochemistry of tumors to be leveraged for therapeutic benefit. 
GSH is the most abundant scavenger molecule in mammalian cells; in the presence of 
the enzyme glutathione peroxidase, GSH reduces toxic free radicals, preventing them 
from oxidizing cellular components [4]. By increasing their GSH levels cancer cells 
become resistant to oxidative stress, including the one induced by chemotherapy or 
ionizing radiation [5].  When comparing redox-sensitive nanomedicines with their non-
redox sensitive counterparts, an average increase in the in vivo antitumor activity 
between 13 – 25% has been reported [6].  
Having in mind the promising application of redox-sensitive nanomedicines, our 
collaborators at the Institute of Material Sciences synthesized a cholesterol-based 
copolymer (PC5MA-SS-PEO) with a disulfide bond in the structure to facilitate drug 
release in the reducing environment inside tumor cells (Figure 4.1). Once in aqueous 
media, PC5MA-SS-PEO self-assembles into nanoparticles in which drugs like 
doxorubicin can be incorporated.  
 
Figure 4.1. PC5MA-SS-PEO chemical structure. a) 
Cholesteryl segment.  
 
On the other hand, the successful 
application of nanoparticle drug delivery in cancer 
treatment depends on key characteristics of the 
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formulated nanocarriers such as particle size and drug loading. Several studies 
emphasize the significant effect of the preparation method on the characteristics of 
nanoparticles formed by high molecular weight amphiphilic block copolymers [7, 8]. This 
type of nanoparticles are kinetically frozen aggregates instead of systems in dynamic 
equilibrium [9], which explains the relevance of the preparation method. In this study, 
we compared two of the most common methods summarized in chapter 2: 1) the 
cosolvent removal and 2) the O/W emulsion method. The first method involves the 
dissolution of the polymer and the drug in a water miscible organic solvent followed by 
the addition of water, which triggers polymer aggregation, and the subsequent 
elimination of the organic solvent by dialysis or evaporation. The second method 
requires the dissolution of the drug in a water-immiscible organic solvent followed by the 
addition of the organic solvent to the aqueous phase to form an emulsion. In this case, 
the polymer may be dissolved in the organic phase or may be present in the aqueous 
media in the form of blank nanoparticles. Finally, the organic solvent is removed by 
evaporation, leaving the drug molecules entrapped in the nanoparticles [10]. Despite its 
advantages the dialysis method was not selected for evaluation because preliminary 
experiments showed that very polydispersed nanoparticles (PDI > 0.3) were obtained 
when using this method. Simultaneously, specific process and formulation parameters 
in each preparation method can affect the final properties of the nanoparticles [10-12]. A 
proper identification of significant parameters, through a DOE approach for instance, is 
paramount for the development of nanoparticles with adequate characteristics for in vivo 
administration.   
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The main objective of this chapter was to optimize the loading of doxorubicin 
(DOX) in redox-sensitive nanoparticles formed by PC5MA-SS-PEO (DOX-SS-NPs), by 
testing two methods of preparation as well as different formulation parameters to finally 




4.3.1. Materials  
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc. 
(Waltham, MA, USA). Triethylamine (TEA), acetonitrile (ACN) and N,N-
dimethylformamide were purchased from Fisher Scientific (Boston, MA, USA). 
Dimethylsulfoxide (DMSO), chloroform (Chl), dichloromethane (DCM) and trifluoroacetic 
acid (TFA) were purchase from Sigma-Aldrich (St Louis, Missouri, USA). Spectra/Pro 
dialysis membranes (MWC: 12 kDa) were obtained from Spectrum Laboratories, 
100Inc. (RanchoDominguez, CA, USA). Centrifugal filters were purchased from 
Millipore (Darmstadt, Germany). All chemicals were either analytical or HPLC grade. 
 
4.3.2. Synthesis and characterization of PC5MA-SS-PEO 
The synthesis and characterization of PC5MA-SS-PEO was done in Dr. 
Rajeswari Kasi laboratory at the Institute of Material Science, University of Connecticut. 
The disulfide block copolymer comprising a polymethacrylate block bearing a 
cholesterol moiety and a polyethylene glycol block was synthesized as described in a 
previous publication [13]. 1HNMR was used to confirm the polymer structure and 
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determine the composition of the copolymer while gel permeation chromatography 
(GPC) was employed to establish its number average molecular weight (Mn) and 
polydispersity (PDI).  
 
4.3.3. Preparation of DOX-SS-NPs 
Regardless of the method of preparation, DOX-HCl was initially treated with TEA 
before loading to obtain the deprotonated and less water-soluble form of the drug.  
 
4.3.3.1. Cosolvent removal method  
 DMF was selected as the water miscible solvent to use, because it was able to 
solubilize both the polymer and the drug. Briefly, DOX-HCl was dissolved in DMF at a 
concentration of 0.83 mg/ml. TEA was added to the solution and the mixture was stirred 
overnight to facilitate the deprotonation of DOX-HCl. The next day, 2.5 mg of PC5MA-
SS-PEO were dissolved in 1 ml of DMF using bath sonication for 20 minutes followed 
by the addition of 1 ml of the drug solution in DMF. The polymer-drug mixture was 
stirred for 1 hour at room temperature.  Subsequently, the whole 2 ml of the drug-
polymer solution were added to 3 ml of ultrapure water in a dropwise manner under 
vigorous agitation (600 rpm). After completing the addition, the mixture was stirred for 1 
hour at room temperature and then transferred to a dialysis bag (MWC 12 kDa) and 
dialyzed against ultrapure water for 48 h with frequent water changes. For this method, 
only the effect of the TEA:DOX molar ratio was studied. Two TEA:DOX molar ratios 
were tested: 3:1 and 12:1. The evaluated responses were the average particle size (Z-
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average), polydispersity index (PDI), %drug loading (%DL) and %encapsulation 
efficiency (%EE). 
 
4.3.3.2. O/W emulsion method  
This method was adapted from Kataoka et al [14]. In this case, we studied the 
effect of the TEA:DOX molar ratio and the organic solvent on the properties of the 
nanoparticles using a 22 full factorial design. Two TEA:DOX molar ratios (6:1 and 12:1) 
and two organic solvents (Chl and DCM) were tested.  The evaluated responses were 
the same mentioned in the cosolvent removal method. DOX-HCl was dissolved in 50 µl 
of DMSO and subsequently Chl or DCM containing TEA were added to the mixture for a 
final DOX concentration of 1.24 mg/ml. The mixture was stirred overnight at 300 rpm. 
700 µl of the drug solution were added to a water suspension of blank nanoparticles 
(0.5 mg/ml, final volume 5 ml) in a dropwise manner under vigorous agitation (600 rpm). 
The mixture was sonicated using a probe sonicator (20% amplitude) in between organic 
solvent additions to facilitate the formation of the emulsion (3 sonication cycles, 1 
minute/cycle). Subsequently, the organic solvent was evaporated by vigorously stirring 
the emulsion overnight at 600 rpm.  
 
4.3.3.3. Purification of DOX-SS-NPs 
The following procedure was used to purify DOX-SS-NPs regardless of the initial 
method of preparation. After preparation, nanoparticle suspensions were collected and 
centrifuged at 8000 rpm for 10 minutes to eliminate large precipitates. Filtration through 
a 0.45 µm filter was used for further purification. To eliminate soluble, non-encapsulated 
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drug, ultrafiltration through a 30 kDa filter was used. The ultrafiltration was done by 
centrifugation at 5000 rpm, for 20 minutes at 20ºC. This step was repeated until no drug 
was detected in the filtrate using absorbance at 480 nm to detect DOX. Subsequently, 
the nanoparticles were resuspended to a theoretical concentration of 1 mg/ml and 
stored at 4°C until analysis. 
 
4.3.4. Characterization of DOX-SS-NPs   
 
4.3.4.1. Particle size distribution and morphology  
Z-average and PDI of DOX-SS-NPs (0.1 mg/ml in ultrapure water) were 
measured using a dynamic light scattering (DLS) instrument (Malvern Zetasizer Nano 
Series, Malvern Instruments, UK). Zeta potential was measured using the same 
instrument but adjusting the nanoparticle concentration to 0.5 – 1 mg/ml using 1 mM 
NaCl to ensure that the conductivity of the samples range from 0.2 to 0.3 (mS/ml). The 
morphology of DOX-SS-NPs was imaged by transmission electron microscopy (TEM), 
(Tecnai 12 G2 Spirit BioTWIN, FEI, USA). Specimens were prepared by adding 3 µl of 
the nanoparticle suspension (1 mg/ml) to a carbon film grid followed by incubation 
during 2 minutes and a subsequent wash with 100 µl of a 0.5% uranyl acetate solution 
in ultrapure water. Samples were air-dried before analysis.  
 
4.3.4.2. Determination of drug loading and encapsulation efficiency 
The amount of DOX-loaded into the nanoparticles was determined by high-
performance liquid chromatography (HPLC). Lyophilized nanoparticles were dissolved 
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in a mixture of 60% ACN and 40% DMSO to obtain clear solutions with final 
nanoparticle concentrations of 0.3 mg/ml. Subsequent dilutions were made with mobile 
phase (30% ACN and 70% ultrapure water containing 0.05% TFA) followed by 
centrifugation at 3000 rpm for 5 min to eliminate potential precipitates before analysis. 
The solutions were analyzed using an HPLC apparatus equipped with an autosampler 
and a fluorescence detector (Shimadzu, Kyoto, Japan). A 10 μl sample was injected 
onto a C18 column (5 μm, 250 × 4.6 mm, Agilent, Santa Clara, CA). The flow rate was 1 
ml/min, and the peaks were monitored by fluorescence detection at excitation and 
emission wavelength (Ex/Em) of 480/558 nm. The amount of drug in the samples was 
calculated by interpolation in a standard curve of DOX-HCl.  
 
4.3.5. Statistical Analysis 
For formulations prepared by the cosolvent removal method, the Student’s t-test 
was used to establish statistical differences among conditions. This analysis was 
performed with GraphPad Prism 6 software (GraphPad Inc., San Diego, CA), and P 
values <0.05 were considered significant. For formulations prepared by the O/W 
emulsion method, a full factorial DOE analysis was conducted using Minitab 18 
statistical software (Minitab Inc., State College, PA: Minitab). All experiments were 







4.4. Results and Discussion  
 
4.4.1. Synthesis and characterization of PC5MA-SS-PEO 
Table 4.1 summarizes the molecular characterization of PC5MA-SS-PEO. 
 
Table 4.1. Molecular characterization of the redox-sensitive polymer PC5MA-SS-PEO. 
 
 








PDI C5MA PEO-SS-RAFT 
Theoretical 15 85 24.1 - 
Experimental 17 83 23.4b 1.12 
 
a Weight fraction of each block in the copolymer calculated using 1HNMR spectra by 
comparing the ratio of the integrals of peaks at 5.33 ppm (olefin group in cholesteryl 
moiety) and 3.64 ppm (PEO repeating unit). 
b Number average molecular weight (Mn) determined by GPC at 40°C with 
tetrahydrofuran  (THF) as the mobile phase and polystyrene as the standards. 
 
 
4.4.2. Preparation of DOX-SS-NP 
The method of preparation as well as the specific evaluated formulation 
parameters had a significant impact on the properties of DOX-SS-NPs. The cosolvent 
removal method produced small (Z-average: 60 – 80 nm) and relatively monodispersed 
nanoparticles (PDI: 0.15-0.2) (Figure 4.2). In this method, the rapid decrease in the 
quality of the solvent lead to the formation of small nanoparticles that quickly become 
kinetically frozen, preventing further growth [15]. The TEA:DOX molar radio had a small 
but significant effect on the particle size distribution; nanoparticles prepared with a 
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higher ratio were slightly bigger and more monodispersed. Regarding the morphology of 
the nanoparticles, at a low TEA:DOX ratio mainly spherical homogenous particles were 
observed (Figure 4.3). Once the TEA:DOX ratio increased, cylindrical aggregates were 
also formed. It has been proposed that PEG can form complexes with cations in 
solution leading to a more compact conformation of the PEG chains [16-18]. In our 
case, an interaction between PEG and positively charged TEA accompanied by a 
change in the conformation of PEG may have led to alterations in the packing of the 
polymer chains since a decrease in the curvature of the aggregates (e.g. from spheres 




Figure 4.2. Particle size distribution of DOX-SS-NPs prepared by the cosolvent removal 







Figure 4.3. TEM images of DOX-SS-NPs prepared by the cosolvent removal method. 
Scale bars are 100 nm.  
 
Drug loading for particles prepared by the cosolvent removal method was low 
(0.4 -2.0%) and increased with a higher TEA-DOX ratio (Figure 4.4). The deprotonated 
form of the drug can partition better into the hydrophobic core of the nanoparticles, 
therefore, it is expected that as the amount of TEA in the media increases, the pH 
increases too and the deprotonated form becomes predominant, leading to higher drug 
loading. One possible explanation for the observed low drug loading with this particular 
method of preparation, can be that the assembly of the nanoparticles is slow compared 






Figure 4.4. Drug loading and encapsulation efficiency of DOX-SS-NPs prepared by the 
cosolvent removal method. The Student’s t-test was used to establish significant 
differences among conditions, *p<0.05.  
 
On the other hand, the O/W emulsion method produced bigger nanoparticles 
than the cosolvent removal method (Z-average: 140 – 200 nm) (Figure 4.5). One 
potential explanation for this observation is that the solubility of the polymer in the 
organic solvent increased the mobility of the polymer chains promoting rearranging and 
growth. The DOE analysis revealed that the organic solvent and more notoriously, the 
interaction between the organic solvent and the TEA:DOX molar ratio significantly 
affected Z-average (Figure 4.5). Overall, the use of DCM increased particle size, but 
this effect was more notorious at a higher TEA:DOX molar ratio; at a low TEA:DOX 
molar ratio the size of nanoparticles prepared with Chl and DCM is relatively close 
(161.5 nm vs 167.7 nm) while at a high ratio, nanoparticles prepared with Chl are much 
smaller than those prepare with DCM (142.7 nm vs 204.1 nm). The obtained model for 
size was the following: 
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 Size (nm) = 161.5 + 4.5*(Solvent) - 18.8*(TEA) + 51.0 (Solvent)*(TEA); R-sq = 85.6% 
Where Solvent = 0 for Chl or 1 for DCM and TEA = 0 for a TEA:DOX molar ratio of 6 or 
1 if the TEA:DOX molar ratio is 12.  
All the coefficients in this model were significantly different from zero except the 
TEA coefficient since the effect of the TEA:DOX molar ratio on particle size was not 
significant.  An R-sq value of 85.6% indicates that most of the variation is due to the 
evaluated parameters. However, there is a part of the variation than cannot be 
explained by the model. Factors like the amount of DMSO used during the preparation 
or the sonication process may contribute to this undetermined variation. The statistical 
analysis also indicated that there was a significant effect of the solvent on the 
polydispersity of the nanoparticles. The magnitude of this effect is minimal, being the 
nanoparticles prepared with DCM slightly more polydispersed than those prepared with 
Chl (Figure 4.5).  
Regarding the morphology of the nanoparticles, a similar observation to that 
made for the cosolvent removal method was found; increasing the amount of TEA 
change the morphology of the nanoparticles from relatively homogeneous spheres to 












Figure 4.6. TEM images of DOX-SS-NPs prepared by the O/W emulsion method. Scale 
bars are 100 nm.  
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The drug loading of nanoparticles prepared by the O/W emulsion method (5 - 
14%) was much higher than the one obtained in the cosolvent removal method (0.4 - 
2%), these values are similar to those reported in other publications [20]. Previous 
studies have emphasize that high drug loading can be achieved when employing this 
preparation method [8, 20] due to the interaction between the organic solvent and the 
nanoparticle core leading to deposition of the drug in the core once the solvent has 
evaporated.  On the other hand, the TEA:DOX molar ratio significantly affected drug 
loading and encapsulation efficiency of nanoparticles prepared by the O/W emulsion 
method. For both solvents, drug loading increased as the TEA:DOX molar ratio 




Figure 4.7. Drug loading and encapsulation efficiency of DOX-SS-NPs prepared by the 
O/W emulsion method. 
 
As highlighted by Kataoka et al [14], a key factor in achieving a high drug loading 
is to increase the partition of DOX from the aqueous phase to the organic phase, which 
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depends on the level of protonation of DOX that decreases when the TEA:DOX molar 
ratio increases making the drug more hydrophobic and therefore increasing its 
concentration in the organic phase. The organic solvent also had a significant effect on 
drug loading and encapsulation efficiency, being DCM the solvent leading to greater 
drug entrapment. A faster evaporation rate of DCM compared to Chl may decrease the 
diffusion of drug from the organic phase to the aqueous phase facilitating higher drug 
entrapment. The obtained models for %drug loading and %encapsulation efficiency 
were the following: 
%Drug Loading = 3.9 + 4.0*(Solvent) + 5.2*(TEA); R-sq = 83.6% 
%Encapsulation Efficiency = 15.2 + 15.7*(Solvent) + 21.6*(TEA); R-sq = 83.2% 
Where Solvent = 0 for Chl or 1 for DCM and TEA = 0 for a TEA:DOX molar ratio of 6 or 
1 if the TEA:DOX molar ratio is 12. 
All the coefficients in this model were significantly different from zero. R-sq 
values around 83% indicate that most of the variation is due to the evaluated 
parameters. However, there is a part of the variation than cannot be explained by the 
model. Factors mentioned above such as amount of DMSO and sonication may have 
contributed to this undetermined variation. Interestingly, a positive and significant linear 
correlation between particle size and drug loading was observed when analyzing data 
from both methods of preparation (Figure 4.8).  
The characterization of DOX-SS-NPs is summarized in Table 4.2. In order to 
select a formulation for subsequent testing, we considered three criteria: 1) average 
particle size ideally below 100 nm, 2) high drug loading to maximize the amount of drug 
reaching tumor tissues and 3) homogeneous morphology of the nanoparticles. Since 
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none of the formulations simultaneously meet the above criteria, we selected 
Formulation 2 and Formulation 4 for further testing.  Formulation 2 was selected 
because its particle size distribution seemed optimal for tumor accumulation via the 
EPR effect while Formulation 4 was selected because its higher drug content may allow 
for higher drug concentrations in tumor tissues. Both formulations were homogeneous 























TEA:DOX Organic solvent 
Z-average 
(nm) PDI Shape 
%Drug 
loading %EE 
1 CR  3 DMF 61.4 ± 4.4 0.21 ± 0.01 Spherical 0.5 ± 0.2 2.0 ± 0.6 
2 CR  12 DMF 71.0 ± 6.6 0.16 ± 0.03 Spherical 1.9 ± 0.7 7.7 ± 3.1 
3 O/W  6 Chl 161.5 ± 12.7 0.16 ± 0.04 Spherical 4.6 ± 0.6 18.5 ± 2.4 
4 O/W  6 DCM 167.7 ± 3.6 0.17 ± 0.02 Spherical 7.6 ± 1.5 30.2 ± 5.9 
5 O/W  12 Chl 142.7 ± 12.0 0.1 ± 0.02 Irregular 8.8 ± 0.3 35.1 ± 1.1 




In this formulation study, we observed a significant influence of the method of 
preparation on the properties of drug-loaded nanoparticles. Consequently, for each 
method of preparation, critical formulation parameters were identified. However, 
variation due to factors that were not evaluated seems to account for an important 
fraction of the observed differences (~15%). Future identification of those factors can 
improve the reproducibility of the nanoparticle preparation process. Two formulations 
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Chapter 5.  
 
In vitro Evaluation of a Cholesterol-based Polymeric Nanoparticle Formulation for 
Bioresponsive Release of Doxorubicin in Tumor Cells: Impact of Nanoparticle 







































Two redox-sensitive polymeric nanoparticle formulations containing DOX 
(Formulation 2 and Formulation 4) were identified as adequate for in vivo administration 
based on their particle size distribution, shape and drug loading. This chapter describes 
the in vitro evaluation of Formulation 2 and Formulation 4 in terms of drug release, 
cytotoxic activity in cancer cells, intracellular distribution and long-term storage stability. 
The redox-sensitive character of these formulations was confirmed as in vitro drug 
release increased under reducing conditions while a comparison with the commercial 
liposomal form of DOX (Doxil®), whose release was not affected by the reducing status 
of the media, emphasizes the specificity of the drug release mechanisms in the redox-
sensitive nanoparticles (DOX-SS-NPs). Significant differences between formulations 
were observed regarding their in vitro performance. Interestingly, the impact of the 
method of preparation extended beyond nanoparticle properties to release kinetics and 
cytotoxic activity. Finally, the results from this extensive in vitro evaluation suggest that 
Formulation 4 is the most promising formulation.  
 
5.2. Introduction 
Once drug-loaded nanoparticles have been prepared and characterized in terms 
of particle size and drug loading, there are some additional in vitro tests that can unveil 
important attributes of the formulations such us drug release, storage stability and 
cytotoxic activity. Conducting these tests facilitates a comprehensive characterization of 
the developed formulations and sheds light onto their potential in vivo performance. 
Having two promising doxorubicin-loaded redox-sensitive nanoparticle formulations, it 
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was important to conduct further in vitro testing to confirm their redox-sensitive 
properties and make an informed selection for subsequent in vivo studies.   
Despite several nanoparticle-based products on the market and many more in 
clinical trials, there are not regulatory standards or compendial methods for in vitro 
release testing of these type of dosage forms. However, several non-compendial 
methods have been described in the literature [1, 2]. All these methods required 
separation of the free drug from the colloidal particles before quantification which can be 
challenging due to the small size of the carriers. Among the most commonly used 
methods are: 1) the sample and separate method and 2) the dialysis method. In the 
sample and separate method, the nanoparticulate dosage form is in the release media, 
under constant temperature and constant agitation. Drug release is asses by sampling 
the release media followed by ultrafiltration with centrifugation to recover only the free 
drug. In the dialysis method, the nanoparticles are separated from the release media 
though a dialysis membrane, the system is kept under constant temperature and 
constant agitation and samples of free drug solution are taken from the reservoir across 
the membrane, no additional separation steps are required. However, drug transport 
through the membrane may delay the detection of released drug and provide and 
inaccurate release profile. Release studies are usually performed at 37ºC to mimic 
physiological temperature. Additional considerations include release media and 
agitation. The type of release media depends on the intended site of administration and 
site of action as well as drug solubility and stability, assay sensitivity, and the method 
used. Sink conditions are preferable whenever possible. On the other hand, agitation is 
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used to prevent nanoparticle aggregation and can be selected using physiological 
considerations [3].  
In vitro cytotoxicity in cancer cells can provide indirect information regarding drug 
release from the nanoparticles. In order to kill cancer cells, free DOX needs to reach its 
intracellular target: the cell nucleus. Therefore, the level of cell death depends on drug 
release since encapsulated drug is completely inactive. We evaluated the cytotoxic 
effect of Formulation 4 and Formulation 2 in A549 human lung cancer cells and 
compared them with DOX-HCl and Doxil®. This cell line was considered pertinent 
because small cell lung cancer is one of the clinical indications of DOX.  
Due to their high surface: volume ratio and high surface energy, nanoparticles 
tend to aggregate and settle; therefore long-term colloidal stability of nanoparticles is 
challenging. In order to confer adequate stability, we introduced PEG into the structure 
of the disulfide cholesterol-based copolymer PC5MA-SS-PEO. PEG’s hydrophilic nature 
is intended to stabilize the nanoparticles through the short-range repulsive hydration 
forces [4]. Having stable nanoparticles in suspension facilitates their use and translation 
to the clinic so stability is an important property to evaluate when developing a 
nanoparticle-based dosage form. In this particular case, we expect that the PEG in the 
nanoparticles will provide optimal colloidal stability in long term storage. Stability of 
Formulation 2 and Formulation 4 at 4ºC was evaluated in the present study over a 4-
month period.  
In summary, the main objectives of this chapter were to 1) study the in vitro 
performance of Formulation 2 and Formulation 4 and compare them to Doxil®, 2) 
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confirmed the redox-sensitive nature of the carriers and 3) select the most promising 
formulation for future in vivo studies based on in vitro testing results.  
 
5.3. Methods 
5.3.1. Materials  
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc. 
(Waltham, MA, USA). Triethylamine (TEA), acetonitrile (ACN), N,N-dimethylformamide, 
polysorbate 80, acetic acid, sodium acetate, potassium chloride, sodium monobasic 
phosphate, potassium dibasic phosphate and sodium chloride were purchased from 
Fisher Scientific (Boston, MA, USA). Dimethylsulfoxide (DMSO), dithiothreitol (DTT), 
chloroform (Chl) dichloromethane (DCM) and trifluoroacetic acid (TFA) were purchase 
from Sigma-Aldrich (St Louis, MO, USA). 0.5% Trypsin and RPMI 1640 were purchased 
from ThermoFisher Scientific (Waltham, MA, USA). Human lung cancer cell line (A549) 
was purchased from the American Type Culture Collection (Manassas, VA, USA). Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, GA, USA). 
Commercially available Doxil® (Janssen, Horsham, PA) or equivalent doxorubicin 
hydrochloride liposome (Dr. Reddy’s, Princeton, NJ) at a stock concentration of 2 mg/ml 
were used as controls. Spectra/Pro dialysis membranes were obtained from Spectrum 
Laboratories, 100Inc. (RanchoDominguez, CA, USA). Centrifugal filters were purchased 






5.3.2. Preparation and characterization of DOX-SS-NPs 
Formulation 2 and Formulation 4 were prepared as described in Chapter 4 of the 
present document.  
 
5.3.3. In vitro release of DOX from DOX-SS-NPs  
We studied the in vitro release of DOX from Formulation 2 and Formulation 4 
using a sample and separate method [3]. Nanoparticles equivalent to 100 µg of 
doxorubicin were suspended in 10 ml of release media for a final concentration of 10 
µg/ml which guaranteed sink conditions. Two types of release media were employed in 
this study:  
1) Release media pH 7.4: sodium phosphate buffer at a concentration of 0.01 M was 
used to maintain a constant pH of 7.4. The osmolarity of the solution was adjusted to 
guarantee isotonicity using sodium chloride. The release media also contained 
polysorbate 80 at a w/v concentration of 0.1%.  
2) Release media pH 5.0: sodium acetate buffer at a concentration of 0.1 M was used to 
maintain a constant pH of 5.0. The osmolarity of the solution was adjusted to guarantee 
isotonicity using sodium chloride. The release media also contained polysorbate 80 at a 
w/v concentration of 0.1%.  
Adjusting the pH of the release media to 7.4 intended to simulate conditions in 
plasma and the cell cytoplasm while setting the pH to 5.0 intended to mimic the 
conditions inside lysosomes where most nanoparticles accumulate after cell 
internalization. To simulate intracellular reducing conditions, DTT at a concentration of 
10 mM was added to the release media. This concentration equals that of intracellular 
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GSH [5, 6]. The nanoparticle suspensions were incubated in a water bath at 37°C and 
kept under constant agitation at 130 rpm. At selected time intervals (pH 7.4: 1, 4 and 8 
h; pH 5.0: 1, 2, 4, 6, 8 and 24 h), 0.5 ml aliquots were removed from the release media, 
and an equivalent volume of fresh media without nanoparticles was compensated so 
the volume was kept constant at 10 ml during the duration of the study. Sampled 
nanoparticles were not return to the release media. In that sense, total drug 
concentration was different for each time point when calculating % cumulative drug 
release, as described below: 
 
% Cumulative drug release = Released drug (µg/ml) x 100% 
Total drug (µg/ml)  
 
- First time point 
Total drug = 10 µg/ml  
- Second time point   
Total drug = (10 µg/ml) * 10 ml – (10 µg/ml) *0.5 ml  = 9.5 µg/ml 
10 ml 
 
   Ultrafiltration using a 100 kDa filter and centrifugation at 5000 rpm and 20°C for 
20 min was used to separate released DOX from the nanoparticles.  The collected 
samples were stored at -20°C until analysis. DOX in the filtrate was quantified by HPLC 
using the method described in chapter 4 of the present document, samples were diluted 






5.3.4. Stability of DOX-SS-NPs at 4°C 
DOX-SS-NPs were adjusted to a concentration of 1 mg/ml (total mass). Samples 
of 400 µl were stored in glass vials at 4°C. At different time points (2 weeks, 1, 2 and 4 
months), samples were removed from the fridge and their particle size and drug loading 
were measured and compared with the values obtained at day zero.  
 
5.3.5. Cytotoxicity of DOX-SS-NPs in A549 human lung cancer cells  
A549 human lung cancer cells (4000 cells/well) were seeded on 96-well plates 
and cultured in 200 μl of RPMI supplemented with 10% FBS for 24 h at 37 °C and 5% 
CO2.  After incubation, media was removed and various concentrations of blank 
nanoparticles (0.2−60 µg/ml), DOX-SS-NPs (Formulation 2 and Formulation 4), Doxil® 
and DOX-HCl (0.02- 6 μg/ml of DOX equivalents) suspended in RPMI with antibiotics 
were added to the cells. DOX-NPs, the non-cleavable formulation discussed in chapter 
3 was also evaluated for comparison. After 72 h of incubation with the different DOX 
formulations, cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-3,5-
diphenyltetrazolium bromide dye conversion (MTT dye, final concentration of 0.25 
mg/ml). Media from the wells was removed and 100 µl of MTT dye dissolved in RPMI 
without supplements were added to each well. Subsequently, plates were incubated for 
4 h at 37 °C and 5% CO2 to allow the dye conversion to occur. Finally, the supernatant 
from each well was removed and the precipitated dye crystals were dissolved in 200 µl 
of DMSO. The absorbance of each well at 540 nm was determined using a microplate 
reader (Tecan Group Ltd., Männedorf, Switzerland), using 690 nm as a reference 
wavelength. Blank-redox sensitive nanoparticles used in this study were prepared 
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according to the cosolvent removal method described in chapter 4 of the present 
document. 
 
5.3.6. Internalization of DOX-SS-NPs by A549 human lung cancer cells  
To study cellular internalization, A549 cells were seeded at a density of 50,000 
cells/well in an 8-well chamber slide and pre-incubated for 24 h at 37°C and 5% CO2. 
Subsequently, media form each well was removed and 500 µl of serum-free RPMI 
containing DOX-HCl, Doxil® or DOX-SS-NPs (Formulation 2 and Formulation 4) at an 
equivalent DOX concentration (10 μg/ml) were added to each well, followed by 
incubation for 4 h at 37 °C. DOX-NPs, the non-cleavable formulation discussed in 
chapter 3 was also evaluated for comparison. Subsequently, cells were rinsed with PBS 
and fixed with a 4% formaldehyde solution for 10 min followed by three washes with 
PBS. After drying, cover glasses were put on top of the slides. Cellular uptake of DOX-
HCl, Doxil®, DOX-NPs  and  DOX-SS-NPs was imaged by confocal laser scanning 
microscopy using a A1R spectral confocal microscope (Nikon, Tokyo, Japan) at an 
excitation/emission wavelength of 490/558 nm.  
 
5.3.7. Statistical Analysis 
In vitro release profiles were compared by difference factor (f1) and similarity 
factor (f2) analysis using the add-in program DDSolver [7]. For the cytotoxicity studies, 
IC50 values were calculated using GraphPad Prism 8 software. All experiments were 




5.4. Results and Discussion  
 
5.4.1. In vitro release of DOX from DOX-SS-NPs 
Release of DOX from redox-sensitive formulations and Doxil® was studied at pH 
7.4 (plasma conditions) and pH 5.0 (lysosome conditions) using the sample and 
separate method. This method was selected because higher free drug recovery was 
observed in preliminary studies when comparing with the dialysis method. The main 
objectives of this in vitro release study were: 1) assess the effect of the preparation 
method on the release kinetics of the nanoparticles and 2) evaluate our initial 
hypothesis that drug release from the nanoparticles would be faster in reducing 
conditions. This particular in vitro release study was not conceived to establish and in 
vitro/in vivo correlation. We focused on early time points since slow intracellular drug 
release was the particular issue that we were trying to address by developing a redox-
sensitive platform; generally, non-cleavable nanoparticles, including Doxil® , fail to 
release a significant amount of DOX in the first 24 hours after being internalized by 
cancer cells [8, 9]. Therefore, studying drug release between 0 – 24 hours was our 
primary target.  
To test the redox-sensitive character of the nanoparticles, DTT was incorporated 
as a reducing agent in the release media. The possibility of DTT activity loss with 
extended incubation time [9] was another reason for not conducting the in vitro release 
studies beyond 24 hours.   
On the other hand, due to DOX instability at pH 7.4 [11], the release study at this 
pH was conducted for 8 h instead of 24 h so drug loss due to degradation was minimal. 
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One of our main focus when studying drug release at pH 7.4 was to potentially assess 
the risk of excessive burst release upon injection into the circulation and long incubation 
periods  were not required to answer this question.   At pH 7.4, Formulation 2 and 
Formulation 4, displayed a two-phase release profile with an initial burst release (0 -1 h) 
followed by sustained release (1 h – 8 h) (Figure 5.1).  During the burst release phase, 
Formulation 2 released about 2.5% of the initial drug content while release from 
Formulation 4 was closed to 14%. On the other hand, Doxil® released 20% of its drug 
load in the same time period. These results suggest that burst release immediately after 
injection may not be a big concern for our redox-sensitive formulations since in both 
cases total burst release was less than that of the commercial reference product.  Both 
redox-sensitive formulations released less than 25% of the total drug content over an 8 
hour period (Figure 5.1A). In both cases, drug release rates decreased over time, a 
classic behavior of systems in which the concentration of drug molecules close to the 
surface is depleted as time progresses [12] (Figure 5.1B). The initial release rate of 
Formulation 4 was greater than the release rate of Formulation 2, suggesting that the 
drug in Formulation 4 is in a region more accessible to the release media. These results 
indicate that DOX release from Formulation 2 and Formulation 4 will be slow in plasma-
like conditions which is important because it prevents high concentrations of free drug in 





Figure 5.1. In vitro release of doxorubicin from redox-sensitive nanoparticles and Doxil® 
at pH 7.4, 37◦C and 130 rpm. A) Cumulative release. B) Calculated Release rate. Data 
are expressed as mean ± SD of three independent experimental replicates. 
 
Drug release from Doxil® at pH 7.4 was faster than release from the redox-
sensitive formulations, being 34% of the initial content released after 8 hours. The 
presence of a reducing agent in the media, slightly increased the release rates for both 
redox-sensitive formulations at early time points (Figure 5.1B). However, release in 
reducing conditions was not greater than 30% of the initial drug content in the 
nanoparticles for both formulations after 8 hours (Figure 5.1A). DOX release from Doxil® 
under reducing conditions did not displayed a clear trend when compared to release in 
non-reducing conditions (Figure 5.1A).  
On the other hand, at pH 5.0, for all formulations, release rates increased 
compared to pH 7.4 (Figure 5.2A). Being a weak base with pKa 7.2 – 8.2 [13, 14], the 
solubility of DOX and its partition into the aqueous phase augment as pH decreases, 
explaining faster release at lysosome-like conditions. Release at pH 5.0 also displayed 
a biphasic profile in both redox-sensitive formulations; being release from Formulation 4 











































































faster than release from Formulation 2. Formulation 2 displayed very little burst release 
(less than 10% after 1 hour) while burst release from Formulation 4 was substantial 
(more than 20% after 1 hour). Burst release at pH 5.0, inside the lysosome, will provide 
free drug available to reach the intracellular target rapidly after internalization by cancer 
cells. Faster drug release from Formulation 4 suggests that in this formulation drug 
molecules can be located in areas closer to the surface of the nanoparticles while in 
Formulation 2 drug molecules may be restricted to inner parts of the core, making their 
transfer to the release media slow. Differences in the zeta potential values for both 
formulations (Formulation 4 +3.4 mv; Formulation 2 -1.7 mv) indicate a potential 
interaction of drug molecules (a protonated and positively charged fraction) with the 
slightly anionic PEG segments in the case of Formulation 4. In this formulation, drug 
molecules in the PEG shell region can be easily transferred to the release media 
explaining faster drug release and greater burst release in Formulation 4.  
At pH 5.0 as well as pH 7.4, the redox sensitive formulations displayed a release 
profile in agreement with monolithic or matrix-type devices where the drug is 
homogenously dispersed in the polymeric matrix. These type of devices generally 
exhibit an initial burst release from the surface and release rate decreases over time as 
the distance that the drug molecules have to cover to reach the release media 
increases with time [15]. Similarly to what was observed at pH 7.4, under non-reducing 
conditions release from Doxil® was faster than release from any of the redox-sensitive 
formulations. The addition of a reducing agent accelerated drug release from 
Formulation 2 and Formulation 4 (Figure 5.2). On the contrary, drug release from 
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Doxil®, at pH 5.0, did not change in a reducing environment, highlighting the specificity 
of the drug release mechanism from DOX-SS-NPs.  
We used the difference factor and similarity factor analysis to identify differences 
in the release profiles of Formulation 2 and Formulation 4 at pH 5.0. Regardless of the 
reducing status of the media, f1 was bigger than 15 and f2 was below 50, indicating that 
the compared release profiles were not equivalent. In other words, release from 
Formulation 4 was significantly faster than release from Formulation 2 in both reducing 
and non-reducing conditions. Interestingly, the use of different methods for the 
preparation of Formulation 2 and Formulation 4 led to marked differences in the in vitro 
drug release profile, likely due to differences in the distribution of the drug molecules in 
the nanoparticles. This finding underscores the importance of evaluating different 
preparation methods when developing drug-loaded nanoparticles from amphiphilic block 
copolymers. The same analysis was conducted to determine the effect of the 
introduction of a reducing agent in the release media. For both formulations 
(Formulation 2 and Formulation 4), the release profiles significantly changed under 
reducing conditions, confirming that drug release from these nanoparticles can be 





Figure 5.2. In vitro release of doxorubicin from redox-sensitive nanoparticles and Doxil® 
at pH 5.0, 37◦C and 130 rpm. A) Cumulative release. B) Data are expressed as mean ± 
SD of three independent experimental replicates. 
 
Drug release is a kinetic process, therefore, the change in release rate over time 
can give us an idea of its order respect to drug concentration in the nanoparticles and 
the driving forces behind the process. For both redox-sensitive formulations, drug 
release rates decreased exponentially over time (Figure 5.2B), in agreement with a first 
order process in which concentration gradient is an important driving force for drug 
release. After the initial burst release phase (0 -1 h), the release profiles of the redox-
sensitive nanoparticles, fitted a first order kinetic model in which release rate depends 
on the remaining amount of drug in the nanoparticles [15] (Figure 5.3): 
Q = 100(1-e-kt) or the linear form ln(100 - Q) = ln100 – kt 
Where Q is the cumulative release percentage, k is the release rate constant and t is 
the time (h).  











































































Figure 5.3. Determination of the release constant using a first order model. A) 
Experimental data for Formulation 2. B) Experimental data for Formulation 4. Data are 
expressed as mean ± SD of three independent experimental replicates. 
 
Release constants were calculated using the linear form of the model (Table 5.1). 
Constants increased when a reducing agent was present in the media and this increase 
was statistically significant for Formulation 4. In the case of Doxil®, release did not fit the 
model described above and therefore a release constant was not calculated.  
 
Table 5.1. Calculated in vitro release constants  
 
Formulation k (h-1) R2 
Formulation 2 0.0105 ± 0.004 0.9812 
Formulation 2 DTT 0.0162 ± 0.005 0.9238 
Formulation 4 0.0114 ± 0.001 0.9631 
Formulation 4 DTT 0.0317 ± 0.009a,b 0.9805 
 
a Release constant is significantly different from the release constant of Formulation 2. 
b Release constant is significantly different from the release of Formulation 4.   
y = -0.0105x + 4.5726
R² = 0.9812














y = -0.0114x + 4.3044
R² = 0.9631

















Based on the first order model described above, we calculated the time it would 
take for each formulation to achieve 99% drug release; 18 days in the case of 
Formulation 2 that can be reduced to 11 days under reducing conditions and 16 days 
for Formulation 4 that get reduced to 6 days in the presence of DTT. These calculations 
highlight the role of redox-triggered strategies on facilitating fast and complete drug 
release from nanoparticles.   
 
5.4.2. Stability of DOX-SS-NPs at 4°C 
The stability of Formulation 2 and Formulation 4 at 4ºC was evaluated over a 4-
month period. Formulation 2 displayed colloidal stability up to 2 months; after 4 months, 
an increased in both the average particle size and the PDI was observed (Figure 5.4A). 
On the contrary, Formulation 4 displayed adequate colloidal stability across the duration 
of the study (Figure 5.5A). Regarding drug stability, both formulations preserved above 
95% of the original drug content up to 2 months in storage but after 4 months, drug 
content felt to 91.4% and 83.0% for Formulation 2 and Formulation 4 respectively 
(Figures 5.4B and 5.5B). As mentioned before, pH plays a key role in the stability of 
DOX. For example, in the commercial form of DOX-HCl solution the pH is adjusted to 
3.0 since it is known that the stability of DOX improves at low pH. The fact that pH was 
not controlled in this stability study, potentially ranging from 6.5 – 7.0 may have been a 
source for drug instability. Further efforts to improve the long term stability of these 






Figure 5.4. Storage stability of Formulation 2 at 4ºC. A) Colloidal stability. B) Drug 
content over time. Data are expressed as mean ± SD of three independent 
experimental replicates.  
 
 
Figure 5.5. Storage stability of Formulation 4 at 4ºC. A) Colloidal stability. B) Drug 






5.4.3. Cytotoxicity of DOX-SS-NPs in A549 human lung cancer cells  
Significant differences were observed when comparing the cytotoxic activity of 
Formulation 2 and Formulation 4 in A549 human lung cancer cells (Figure 5.6A). At 
equivalent DOX concentrations, Formulation 4 killed more cells than Formulation 2. 
These discrepancies can be a consequence of their differences in terms of drug 
release; the formulation with fastest drug release was subsequently more efficacious in 
vitro. Blank nanoparticles with no loaded drug did not affect cell viability, therefore, the 
cytotoxic activity observed for Formulation 2 and Formulation 4 is entirely due to the 
presence of doxorubicin. Being Formulation 4 the most cytotoxic of the redox-sensitive 
formulations, we compared its activity to DOX-HCl and Doxil® in terms of in vitro 
anticancer effect (Figure 5.6B).  As expected, DOX-HCl displayed the greatest cytotoxic 
activity, being molecular DOX a compound with high cell membrane permeability that 
quickly reaches its intracellular target it is usually the most potent form of the drug in 
vitro. Formulation 4 was slightly but significantly more cytotoxic than Doxil®, as denoted 
by their respective IC50 values (Table 5.2). Formulation 4 was also significantly more 
cytotoxic than DOX-NPs, the non-cleavable nanoparticles studied in chapter 3, 
indicating improvement compared to the first type of cholesterol-based nanoparticle 








Figure 5.6. Effect of different formulations of doxorubicin on the viability of A549 human 
lung cancer cells. A) Comparison between redox-sensitive formulations. B) Comparison 
between Formulation 4 and commercial formulations. Data are expressed as mean ± 
SD of at least three independent replicates. 
 
Table 5.2. IC50 values for different doxorubicin formulations 
 
Formulation IC50 (ng/ml) 95% CI (ng/ml)a 
DOX-HCl 56.8 40.3 - 80.1 
Doxil® 627.8 462.6 - 852.1 
Formulation 2 1212 921.3 - 1596 
Formulation 4 250.8 213.5 - 294.6 
DOX-NPs 1757 1416 - 2181 
 













































































5.4.4 Internalization of DOX-SS-NPs by A549 human lung cancer cells 
Four hours after the addition of DOX-HCl to the cell culture most of the 
fluorescent signal localized in the nucleus of the cells (Figure 5.7). Rapid diffusion of 
free DOX across the cell membrane and subsequent translocation into the cell nucleus 
have been extensively reported [16, 17], although it is unclear if the drug is transported 
to this organelle by passive diffusion or by carrier-mediated transportation [18]. 
Depending on the drug concentration, nuclear accumulation of DOX can be 2 - 4 times 
higher than the accumulation in other regions of the cells [17, 19], this particular 
distribution is facilitated by the strong interaction between DOX and DNA; the 
anthracycline ring in DOX intercalates into the DNA base pairs forming complexes with 
the adenine-thymine and the guanine-cytosine regions respectively [20]. In the case of 
the redox sensitive formulations, interesting differences in the intracellular distribution of 
DOX were found. When cells were exposed to Formulation 2, DOX was detected mainly 
in the cytoplasm of the cells, suggesting effective nanoparticle internalization but 
minimal release. In the case of Formulations 4, fluorescence signal was found in the 
cytoplasm, indicating nanoparticle internalization, as well as in the cell nucleus, 
suggesting rapid drug release since nanoparticles are too big to cross the nuclear pores 
and accumulate as intact carriers in the nucleus so only free drug can be detected in 
this organelle (Figure 5.7). These results seemed to agree with the results of the in vitro 
release study; since Formulation 4 releases the drug significantly faster than 
Formulation 2 drug delivered by Formulation 4 reaches the cell nucleus faster than drug 
delivered by Formulation 2. Formulation 4 seemed to overcome the slow drug release 
and subsequent absence of doxorubicin in the cell nucleus observed with DOX-NPs, the 
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first type of cholesterol-based nanoparticle developed in the laboratory (chapter 3). No 
fluorescence signal was detected in cells exposed to Doxil®. Seynhaeve et al also 
reported little intracellular internalization of Doxil® at early time points (0 – 3 h) 
compared to DOX-HCl. The authors in this paper stated that in the first three hours of 
exposure the majority of Doxil® appeared loosely adhered to the membrane, being 
washed away upon medium change so that longer incubation times were required to 
observe intracellular Doxil® at the same imaging conditions used for DOX-HCl [7]. Our 
observation then seems to be a true representation of the slow internalization of Doxil® 
in cancer cells. As a consequence, rapid nuclear accumulation of DOX when 





Figure 5.7. Intracellular distribution of DOX delivered by different formulations. TM 
stands for transmitted light. Scale bars represent 20 µm.  
 
5.5 Conclusions 
After comprehensive in vitro evaluation, the redox-sensitive nature of 
nanoparticles prepared with PC5MA-SS-PEO was confirmed by increased in vitro drug 
release in reducing conditions. Additionally, significant differences in the rate and extent 
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of the in vitro drug release, the cytotoxic activity in cancer cells and the intracellular 
distributions of DOX were observed between Formulation 2 and Formulation 4, 
suggesting that the method of preparation can not only affect the properties of drug-
loaded nanoparticles but also their performance.  
On the other hand, results from the cytotoxicity study and the intracellular drug 
distribution study indicate that the redox-sensitive nanoparticles overcame the issue of 
slow release associated with DOX-NPs, the non-cleavable nanoparticles evaluated in 
chapter 3.  
Due to faster drug release and greater cytotoxic activity, Formulation 4 seems to 
be the best candidate to advance to in vivo efficacy and toxicity studies, however, 
concerns regarding the effect of particle size in tumor accumulation require that a 
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This chapter describes the comparison, in terms of in vivo distribution, between 
two redox-sensitive formulations (Formulation 2 and Formulation 4) in order to select 
the best candidate for in vivo efficacy studies. Subsequently, the process of dose 
selection for DOX-SS-NPs, DOX-HCl and Doxil®, based on tolerability studies in healthy 
SCID mice is depicted, as well as the results regarding the effects of DOX-HCl, Doxil® 
and DOX-SS-NPs on tumor growth and survival of tumor-bearing SCID mice. Overall, 
DOX-SS-NPs effectively accumulated in tumor tissues while no accumulation 
differences between Formulation 2 and Formulation 4 were found. Encouraging results 
regarding tumor growth inhibition when treating tumor bearing mice with DOX-SS-NPs 
were observed as well as significant improvement in the safety profile compared to the 
free form of the drug.  
 
6.2. Introduction  
DOX is a potent and commonly used cytotoxic anticancer drug with severe and 
dose-limiting side effects. The administration of DOX can cause chronic heart damage, 
myelosuppression, hepatotoxicity and alterations in the epithelium of the intestine 
among other multi-organ side effects [1]. Safer and effective alternatives to conventional 
doxorubicin hydrochloride (DOX-HCl), the soluble non-encapsulated form of DOX, have 
been of great interest in order to reduce the risk of life-threatening adverse reactions 
and extend doxorubicin use to high-risk populations such as patients with pre-existing 
cardiac conditions. In 1995, the FDA approved a pegylated liposomal formulation of 
DOX, commercially known as Doxil®, for the treatment of Kaposi sarcoma, a type of 
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cancer produced by a viral infection and common among HIV-infected patients. Since 
then, the indications of Doxil® have expanded to ovarian cancer and multiple myeloma. 
In terms of tolerability, the use of Doxil® reduces the incidence of cardiac toxicity (when 
compared to DOX-HCl) and myelosuppression [2]. Despite this superiority, Doxil® can 
induce unique and dose-limiting side effects; 1) desquamating dermatitis, known as 
palmar plantar erythrodysthesia (PPE) or “foot and hand syndrome” and 2) a type of 
acute hypersensitivity denominated complement activation-related pseudo-allergy 
(CARPA) [3]. These side effects, particularly PPE, limit the maximum dose of Doxil® that 
can be administered to 50 mg/m2 IV every 4 weeks which does not translate into 
superior efficacy when compared to the standard of care [2]. 
Given the need for safer and especially more efficacious alternatives to DOX-HCl 
and Doxil®, we previously demonstrated that the encapsulation of DOX into cholesterol-
based polymeric nanoparticles reduced the toxicity of the drug while preserving some of 
the anti-tumor activity (see chapter 3 of the present document). Subsequently, we 
incorporated a disulfide bond in the polymer structure to facilitate drug release and 
potentially improve the efficacy of these novel nanomedicines. After extensive 
optimization and in vitro evaluation of different redox-sensitive formulations, two 
promising candidates were identified: Formulation 2 and Formulation 4. The objectives 
of this chapter were to 1) select a final redox-sensitive formulation based on the in vivo 
distribution of the nanoparticles and 2) evaluate the in vivo safety and efficacy of this 







6.3.1. Materials  
Doxorubicin hydrochloride (DOX-HCl) was purchased from Biotang Inc. 
(Waltham, MA, USA). Triethylamine (TEA), acetonitrile (ACN), N,N-dimethylformamide 
and sodium chloride were purchased from Fisher Scientific (Boston, MA, USA). 
Dimethylsulfoxide (DMSO), dichloromethane (DCM) and trifluoroacetic acid (TFA) were 
purchase from Sigma-Aldrich (St Louis, MO, USA). Draq5, 1,1′-dioctaecyl-3,3,3′,3′-
tetramethylindotricarbocyanine iodide (DiR) was obtained from Invitrogen (Carlsbad, 
CA, USA). Trypsin (0.5%) and RPMI 1640 were purchased from ThermoFisher 
Scientific (Waltham, MA, USA). A549 human lung cancer cell line was purchased from 
the American Type Culture Collection (Manassas, VA, USA). Fetal bovine serum (FBS) 
was purchased from Atlanta Biologicals (Norcross, GA, USA).	Commercial Doxil® 
(Janssen, Horsham, PA) or doxorubicin hydrochloride liposome (Dr. Reddy’s, Princeton, 
NJ) at a stock concentration of 2 mg/ml were used as controls. Spectra/Pro dialysis 
membranes were obtained from Spectrum Laboratories, 100Inc. (RanchoDominguez, 
CA, USA). Centrifugal filters were purchased from Millipore (Darmstadt, Germany). All 
chemicals were either analytical or HPLC grade. 
 
6.3.2. In Vivo Biodistribution of DiR-SS-NPs 
All animal studies were performed according to an approved protocol by 
Institutional Animal Care and Use Committee (IACUC) at the University of Connecticut. 
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The biodistribution of nanoparticles formed by PC5MA-SS-PEO was assessed by 
in vivo near-infrared (NIR) imaging. A NIR fluorophore, DiR, was incorporated into the 
nanoparticles by the cosolvent removal or the O/W emulsion method to obtain 
nanoparticles with similar characteristics to Formulation 2 and Formulation 4. For 
nanoparticles prepared by the cosolvent removal method, 3 mg of redox-sensitive 
polymer were weighted and dissolved in 1.5 ml of DMF using bath sonication. 90 µl of a 
solution of DiR in DMF (2 mg/ml) were added to the polymer solution followed by 
vortexing. The solution of polymer and dye in organic solvent was added to 2 ml of 
ultrapure water in a dropwise manner under vigorous agitation (700 rpm). The mixture 
was stirred for 1 hour at room temperature. Then, the mixture was transferred to a 
dialysis bag (MWC: 12 kDa) and dialyzed against ultrapure water for 48 hours (3 water 
changes total). For nanoparticles prepared by the O/W emulsion method, 75 µl of a DiR 
stock in DMF (2 mg/ml) were added to 625 ul of dichloromethane. This mixture was 
added in a dropwise manner to a suspension of blank-SS-NPs in water (0.5 mg/ml, 5 ml 
total) under vigorous agitation (700-800 rpm). Vortexing during the addition to facilitate 
mixing. Once the addition was completed, probe sonication (2 minutes, 20% amplitude) 
was used to promote emulsion formation. Dichloromethane was evaporated by stirring 
the emulsion overnight. Regardless the method of preparation, nanoparticle 
suspensions were collected and centrifuged at 8000 rpm for 10 minutes to eliminate 
insoluble dye. Subsequently, suspensions were filtered through a 0.45 µm filter. The 
DiR content of was determined by absorbance at 750 nm. 
To obtain an in vivo tumor model, SCID female mice, 8 week old, were implanted 
subcutaneously with 2 million A549 cells in the right hind leg. Tumor growth was 
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monitored twice a week. The study was conducted 4 weeks after tumor cell 
implantation. Mice were imaged before injection for background signal. Subsequently, 
100 µl of the DiR-SS-NPs adjusted to a concentration of 20 µg/ml (DiR equivalents) 
were administered to each mice through tail vain injection (final DiR dose 2 µg/mouse). 
Images were taken right after administration and then 1, 6, 24, 48 and 72 h after 
injection. At time points 6 h, 24 h and 72 hours, mice were euthanized and major organs 
(heart, lung, spleen, liver, kidneys and tumors) were collected and imaged.  
 
6.3.4. In Vivo Dose Tolerability of DOX-SS-NPs 
This study was conducted to determine the effect of repetitive administrations of 
DOX-SS-NPs in SCID mice at a dose toxic when administering DOX-HCl but potentially 
safe when administering DOX-SS-NPs. A dose of 3 mg/kg was selected based on our 
previous experience as well as literature reports [4, 5]. Adult healthy SCID mice (4 
mice/group) were treated once a week with Doxil® or DOX-SS-NPs (Formulation 4) 
equivalent to 3 mg/kg of DOX via tail vein injections. Due to high toxicity at the site of 
injection that prevents frequent i.v administration of DOX-HCl mice in this group were 
injected intraperitoneally. Previous studies have reported similar plasma and liver 
concentrations of DOX after i.v and i.p administration in nude mice even though 
concentrations in other organs like heart and muscle may be affected by the route of 
administration [6]. Blank redox-sensitive NPs and saline solution were given i.v as 
controls.  Body weight was monitored twice a week and a total of six doses were 
administered. At the end of the study mice were euthanized and relevant organs such 
as heart, lungs, liver, spleen and kidneys were collected and fixed with 4% 
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formaldehyde in PBS for histopathological analysis. DOX-SS-NPs (Formulation 4) were 
prepared as described in chapter 4 of the present document. Blank-redox sensitive 
nanoparticles were prepared using the cosolvent removal method described in chapter 
4 of the present document.  
 
6.3.5. In Vivo Efficacy and Safety of DOX-SS-NPs 
The antitumor activity of DOX-HCl, Doxil® and DOX-SS- NPs was evaluated in 
tumor bearing SCID mice inoculated subcutaneously in the right flank with 2 × 106 A549 
cells. When the tumors grew to an average volume between 20 - 30 mm3, mice were 
divided into four treatment groups so the average tumor volume in each group was the 
same (n = 4 - 5): 1 mg/kg DOX-HCl, 3 mg/kg Doxil®, 3 mg/kg DOX-SS-NPs and saline. 
Mice treated with Doxil®, DOX-SS- NPs and saline were injected intravenously while 
DOX-HCl was administered intraperitoneally. Treatment was given once a week for 7 
weeks. The day of the first dose was designated as day 0. Tumor size and body weight 
were monitored three times per week. At the end of the study, mice were euthanized 
and serum and major organs were collected for pathology and biochemical analysis. 
 
6.3.6. TUNEL assay staining 
Tumor tissues from the efficacy study were sent to the University of Connecticut 
Health Center Research Histology Core for terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) staining. Subsequently, images taken with a 4X objective 
were stitched and analyzed to reconstruct the entire tumors [7] and analyzed for % 
stained area using a default algorithm in Image J for thresholding.   
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6.3.7. Alanine aminotransferase (ALT) assay 
ALT plasma levels were determined as a biomarker for liver damage in mice from 
the efficacy study. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc., 
Waltham, MA) was used to determine ALT activity. Briefly, 100 µl of reagent was added 
to 10 µl serum or plasma samples, and absorbance was measured 
spectrophotometrically at 340 nm using a Bio-Tek Power Wave X Spectrophotometer. 
ALT activity (U/l) was determined using the molar extinction coefficient of NADH (6.3 
mM−1 cm−1). 
 
6.3.8 Statistical Analysis 
Analysis of variance and survival curve analysis were performed using GraphPad 
Prism 8 software (GraphPad Inc., San Diego, CA). All experiments were conducted in at 





6.4.1. In Vivo Biodistribution of DiR-SS-NPs 
DiR-SS-NPs prepared by cosolvent removal method had a Z-average of 89.7 nm 
and a PDI of 0.216 while nanoparticles prepared by the O/W emulsion method 
displayed a Z-average of 168.7 nm and a PDI of 0.101. The size distribution of DiR-SS-
NPs resembled Formulation 2 and Formulation 4 respectively. In consequence, DiR-SS-
NPs were used as surrogates for the biodistribution study. For both formulations, liver 
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accumulation was observed early after injection. As time progressed, fluorescence 
signal was detected in tumors, being 24 h the time point when maximum intensity was 
observed. (Figure 6.1 and Figure 6.2).  
 
Figure 6.1. In vivo distribution of DiR-SS-NPs prepared by the cosolvent removal 






Figure 6.2. In vivo distribution of DiR-SS-NPs prepared by the O/W emulsion method 
(Formulation 4). Tumor location is highlighted in red.  
 
Signal from removed organs at 24 and 72 hours confirmed the results observed 
in vivo; for both formulations the liver was the organ with the greatest nanoparticle 
accumulation (60% - 80% of total recovered signal), followed by the spleen (10% - 30%) 
and the lungs (5% - 10%) (Figure 6.3). Nanoparticle accumulation was observed in 
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removed tumor tissues at 24 and 72 h, being the intensity approximately 2% of the total 
recovered signal (Figure 6.4).  
 
 
Figure 6.3. Organ-specific distribution of DiR-SS-NPs, 24 h after injection. Data are 
plotted as mean ± SD of three replicates. % Total signal = (Individual organ radiant 
efficiency per area/Total recovered radian efficiency per area)*100%.  
 
No differences in terms of tumor accumulation were observed between 
Formulation 2 and Formulation 4.   Considering the results from the in vitro evaluation 
and biodistribution, Formulation 4 seemed more promising and therefore was selected 
for the in vivo efficacy and toxicity studies. Formulation 4 will be denoted as DOX-SS-





Figure 6.4. Accumulation of DiR-SS-NPs in subcutaneous tumors. A) Fluorescent 
signal from DiR-SS-NPs in collected tumors. B) Quantification of Fluorescent signal 
from DiR-SS-NPs in collected tumors, 24 h after injection, expressed as percentage of 
total recovered signal. Data are plotted as mean ± SD of three independent replicates.  
 
6.4.2. In Vivo Tolerability of DOX-SS-NPs 
In order to established if a dose of 3 mg/kg DOX-SS-NPs (DOX equivalent) will 
be tolerated in repeated administrations, healthy mice were given weakly doses of 3 
mg/kg DOX-HCl, Doxil® and DOX-SS-NPs while saline and blank nanoparticles were 
given as controls. A total of 6 doses were administered and body weight was monitored 
twice a weak.  
Early in the study, mice treated with DOX-HCl exhibited signs of toxicity such as 
significant weight loss compared to the saline group (Figure 6.5A), hunched posture, 
ruffled fur coats, and low activity; all the mice in this group died by day 20 of the study. 
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Mice treated with Doxil® showed significant weight loss, compared to the saline group, 
close to the end of the study. One of the mouse in this group experienced eye damage 
after two doses; ocular adverse reactions like dry eye and conjunctivitis have been 
reported in the post-marketing surveillance of Doxil® [8] but it is difficult to known if this 
finding is related to the treatment. This mouse also developed diarrhea followed by 
weight loss and dead. In contrast, no adverse effects were observed in mice treated 




Figure 6.5. Tolerability of 3 mg/kg DOX-SS-NPs in healthy SCID mice. All mice 
received 3 mg/kg DOX equivalents regardless of the administered formulation (n = 4).  
A) Effect on body weight. #Statistically significant differences between DOX-HCl and 
saline group, Kruskal-Wallis test, p < 0.05. *Statistically significant differences between 
Doxil® and saline group, Krustal-Wallis test, p < 0.05). B) Effect on survival. *Statistically 






































































significant differences between DOX-HCl and the saline control group, Gehan-Breslow-
Wilcoxon test, p < 0.05.   
 
By the end of the study, survival among groups was 0% for DOX-HCl, 75% for 
Doxil® and 100% for DOX-SS-NPs, Blank NPs and saline (Figure 6.5B). Only the 
survival curve of the DOX-HCl group was significantly different from the survival curves 
of the other treatment groups (Figure 6.5B). It is known that SCID mice are very 
sensitive to the toxic effects of DOX, causing dead at low accumulative doses ranging 
from 6 mg/kg to 12 mg/kg [4, 5]. Our results agreed with these reports. In our case, all 
mice died when the accumulative dose of DOX-HCl reached 9 mg/kg. Even though 
Doxil® is less toxic than DOX-HCl, a previous study observed some toxicity in SCID 
mice at a weekly dose of 3 mg/kg [4]. Accordingly, we observed toxicity in one out of 
four mice treated with Doxil® and despite lack of statistical significance, the fact that no 
toxicity was observe in any of the mice treated with DOX-SS-NPs suggests than our 
formulation could be potentially safer than Doxil®. Regarding the histopathology 
analysis, liver toxicity was a concern for the group treated with DOX-SS-NPs due to 
high glutathione levels in this organ. However, the livers of all mice in the study were 
normal. No evidence of heart, lung or kidney toxicity was found in any group in the 
study. A severe reduction in spleen hematopoiesis occurred in one of the mice treated 
with DOX-HCl (3 doses of 3 mg/kg) while a moderate reduction was observed in one of 
the mice treated with DOX-SS-NPs (6 doses of 3 mg/kg). Despite causing fatal toxicity 
in all the treated mice, organ-specific toxicity that could explain dead was not observed 
in mice treated with DOX-HCl. Besides cardiac toxicity and myelosuppression, DOX-
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HCl can also induce severe intestinal damage [9]. Being weight loss one of the side 
effects observed in the DOX-HCl-treated group, it is possible that intestine toxicity was 
the cause of death in these mice, which could not been confirmed in the pathology 
analysis since intestine samples were not collected. Overall, DOX-SS-NPs at a dose of 
3 mg/kg, once a week, could be administered to healthy mice for at least 6 weeks 
without inducing marked toxicity, therefore, it was decided to use the same dose in the 
subsequent efficacy study.  
 
6.4.2. In Vivo Efficacy of DOX-SS-NPs 
Tumor-bearing SCID mice received 7 weekly doses of 3 mg/kg DOX-equivalents 
of Doxil® or DOX-SS-NPs. Mice in the DOX-HCl group received 7 weekly doses of 1 
mg/kg because it was previously observed that a dose of 3 mg/kg DOX-HCl was very 
toxic for repeated administrations. By the end of the study, the average tumor volume 
was 1301.0 mm3 for the saline group, 908.3 mm3 for the DOX-HCl group, 488.3 mm3 for 
the DOX-SS-NPs group, and 437.8 mm3 for the group treated with Doxil® (Figure 11A). 
(Figure 6.6A).  
When comparing tumor growth between groups, statistically significant 
differences between the saline group and both the DOX-SS-NPs and the Doxil® group 
were found by the end of the study (Figure 6.6B). The inhibitory effect of DOX-SS-NPs 
and Doxil® was also observed in the size and weight of tumors collected by the end of 
the study (Figure 6.7). No significant differences were observed between the DOX-SS-
NPs and the Doxil® treatment. However, it is important to consider that the lack of 
significant differences may be due to large variation and small sample size.  
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Regarding tumor cell death, there were not statistically significant differences 
among groups when analyzing TUNEL staining; overall, tumors were very big by the 





Figure 6.6. Effect of 3 mg/kg DOX-SS-NPs (Formulation 4) on tumor growth. A) Tumor 
volume over time. B) Tumor volume at the end of the study. *Statistically significant 
differences between treatment groups and the saline control group at day 43, one-way 
ANOVA and Dunnet’s test, p < 0.05. Data are expressed as mean ± SD of four to five 
independent experimental replicates.  
 
 


































































































Figure 6.7. Effect of 3 mg/kg DOX-SS-NPs (Formulation 4) on tumor weight and size. 









Figure 6.8. %Tumor area positive for TUNEL staining. Data are expressed as mean ± 
SD of three independent replicates. 
 
In terms of treatment safety, mice in the DOX-HCl group displayed significant 
weight loss, compared to mice in the saline group, after only 3 doses, and their weight 
loss progressed up to the end of the study. Mice in the DOX-SS-NPs group also 
experienced weight loss but only after receiving 6 doses of the treatment and it was not 
statistically significant (Figure 6.9A). By the end of the study, survival among the groups 
was 80% (4/5) for saline, 60% (3/5) for DOX-HCl, 75% (3/4) for Doxil® and 100% (4/4) 
for DOX-SS-NPs, being the treatment with DOX-SS-NPs the only one providing 100% 






Figure 6.9. Tolerability of 3 mg/kg DOX-SS-NPs (Formulation 4) in tumor-bearing SCID 
mice. (n = 4-5).  A) Effect on body weight. *Statistically significant differences between 
DOX-HCl and saline group (Kruskal-Wallis test, p < 0.05. B) Effect on survival.  
 
Results from the pathology analysis are summarized in Table 6.1. All mice 
treated with DOX, regardless of the form, displayed myelosuppression and splenic 
hemosiderosis secondary to hematopoietic toxicity. Splenitis, manifested as 
accumulation of neutrophils in the spleen, was observed in all DOX-treated mice except 
from one mouse in the Doxil® group. Liver atrophy was also a common finding in DOX-
treated mice. This atrophy was characterized by smaller hepatic lobules, smaller 
hepatocytes and depletion of glycogen from the hepatocyte cytoplasm. Since neither 
liver necrosis not fibrosis or inflammation were observed, it is believed that liver atrophy 
could be secondary to the weigh lost and overall emaciation of the mice; once the 
glycogen reserves in the liver are consumed, hepatocyte size and morphology change, 
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which could explain the observed atrophy of the organ. Interstitial pneumonia was found 
in some DOX-treated mice. In the case of the DOX-HCl and DOX-SS-NPs groups, 
interstitial pneumonia could be secondary to lung metastasis because both are 
simultaneously present. Mice treated with Doxil® also developed interstitial pneumonia 
but there were not tumors present in the lungs of these mice. It is possible that this is an 
acute finding produced by anesthesia. On the other hand, lung toxicity, although not 
predominant, has indeed been reported in patients treated with pegylated liposomal 
DOX [10, 11], in some cases resulting in lethal toxicity. However, the absence of lung 
necrosis or fibrosis makes unlikely that interstitial pneumonia was produced by Doxil®. 
One mouse in the Doxil® group displayed myocarditis and pulmonary arteritis while no 
sign of heart toxicity were found in mice treated with DOX-SS-NPs or DOX-HCl. The 
fact that a lower dose of DOX-HCl was used (1 mg/kg) in this study, compared to a 
higher dose of Doxil® and DOX-SS-NPs (3 mg/kg), may explain why cardiac damage 
was not observed in the DOX-HCl group. Finally, moderate enterocolitis was observed 
in one of the mice treated with DOX-SS-NPs but it is unclear if it was produced by the 
treatment of it was due to an unrelated infection. The hypothesis derived from the 
tolerability study that intestine damage could be the cause of rapid weight loss and 
death was not confirmed by the pathological analysis since not intestine damage was 







Table 6.1. Pathologic findings in tumor-bearing mice treated with different forms of DOX 
Mouse Treatment 
Pathologic Findings 
Myelosuppression Splenic hemosiderosis Splenitis Hepatic  atrophy Lung metastasis Interstitial pneumonia Miocarditis 
01 
Saline 
N N N Y (1) Y N N 
07 N N N N N N N 






Y (1) Y (2) Y (3) N N N 
107 Y (4) Y (3) Y (3) Y (2) Y Y N 




Y (4) Y (4) N N N Y N 
03 Y (4) Y (4) Y (2) N N Y Y 




Y (4) Y (4) Y (2) Y (2) Y Y N 
14 Y (4) Y (4) Y (2) Y (3) N N N 
15 Y (4) Y (5) Y (2) Y (3) N N N 
aLesions were scored according to the following scale: (1) minimal, (2) slight, (3) 
moderate, (4) market and (5) severe.  
 
 
Discrepancies in terms of organ-specific effects were observed between the 
tolerability study in healthy mice and the efficacy study in tumor-bearing mice, almost no 
toxicity was observed in the first while the former lead to multiple organ alteration 
findings, especially when looking at the DOX-SS-NPs and Doxil® groups which received 
the same dose in both studies. One potential explanation is that i.v injections were very 
difficult to perform in the tolerability study since they have to be done inside a chemical 
safety cabinet and it took some initial doses to perfect the technique. It is possible that 
mice in the tolerability studied received lower actual doses than mice in the efficacy 
study where there were not injection problems.  
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ALT values increased in mice treated with Doxil® and DOX-SS-NPs, compared to 
the saline group, however, differences were only significant for the latest group (Figure 
6.10). Since only organs and blood from surviving mice were taken for analysis, the 
toxic effects leading to the death of mice in the DOX-HCl and Doxil® groups are 
unknown and results can be bias because they correspond to the mice that experienced 
less toxicity while in the case of DOX-SS-NPs because there were not deaths we have 




Figure 6.10. Serum ALT levels in tumor-bearing mice treated with 3 mg/kg DOX-SS-
NPs. ALT is expressed as international units (IU) per liter, data are plotted as mean ± 
SD of three independent replicates. *Significant differences between 3 mg DOX-SS-




Survival data and the absence of cardiac damage in mice treated with DOX-SS-
NPs suggests that DOX-SS-NPs at a weekly dose of 3 mg/kg was less toxic than the 
same dose of Doxil®. However, a study with a larger sample size will be required to 
establish statistically significant differences among groups. 
 
6.5. Conclusions 
After extensive formulation development and in vitro testing work, the particular 
goals of this part of the dissertation were to 1) select a final redox-sensitive formulation 
from two candidates, based on the in vivo distribution of the nanoparticles and 2) 
evaluate the efficacy and toxicity of this selected formulation in comparison with DOX-
HCl and Doxil®. Formulation 4 was selected for efficacy studies because it displayed the 
best in vitro performance, effectively accumulated in tumor tissues and there were not 
tumor accumulation differences when compared to Formulation 2. After tolerability and 
efficacy testing, it is clear that DOX-SS-NPs (Formulation 4) at a dose of 3 mg/kg is 
safer than DOX-HCl administered at the same dose and did not display the cardiac 
adverse effects and  fatal toxicity observed in mice treated with Doxil®. On the other 
hand, there are encouraging results in terms of effective tumor growth inhibition when 
administering DOX-SS-NPs. However, a study with a larger sample size will be required 
to established, with proper statistical support, the potential differences when comparing 
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Chapter 7.  
























7.1 Summary  
Life-threatening side effects associated to the use of cytotoxic chemotherapeutic 
drugs continuous to be a challenge for cancer treatment. Drug encapsulation into 
nanoparticles is an alternative to reduce drug concentrations in healthy tissues, and the 
subsequent adverse effects, while maintaining or increasing the concentrations that 
reach tumor tissues so the anticancer activity is not compromised. Polymeric 
nanoparticles from amphiphilic copolymers are deemed as flexible delivery platforms 
that efficiently encapsulate hydrophobic drugs and can be tailored to display long term 
plasma circulation, effective extravasation across the leaky tumor vasculature and 
tissue-specific drug release.  
These particular research work involved the formulation and evaluation of 
nanoparticles made from amphiphilic copolymers containing cholesterol (hydrophobic 
block) and PEG (hydrophilic segment), as delivery vehicles for the anticancer drug 
doxorubicin. Initially, we studied the in vivo efficacy and toxicity of DOX encapsulated in 
polymeric nanoparticles (DOX-NPs) made from an amphiphilic brush-like block 
copolymer composed of polynorbornene-cholesterol/polyethylene glycol (P(NBCh9-b-
NBPEG)). The formulation development and initial testing of DOX-NPs had been 
previously reported by our group but comprehensive in vivo evaluation was lacking. 
DOX-NPs proved to be safe for repeated administration. Treatment of tumor-bearing 
mice with DOX-NPs significantly reduced tumor growth without inducing free DOX 
associated cardiac toxicity, liver toxicity or myelosuppression, providing 100% survival 
by the end of the study. The improved safety profile of DOX-NPs derived from low drug 
release in plasma as well as reduced drug accumulation in major organs like heart, liver 
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and spleen. In this case, a greater dose of DOX-NPs (5 mg/kg DOX equivalents) lead to 
similar tumor growth inhibition than 1 mg/kg DOX-HCl (free drug); this need for a higher 
dose when administering DOX-NPs could potentially be due to slow drug release from 
the nanoparticles. Limited nuclear accumulation of DOX was observed when exposing 
cancer cells DOX-NPs, suggesting that slow drug release was preventing the drug from 
reaching its intracellular target. Therefore, incorporation of a biologically relevant 
cleavable functional group in the polymer structure was proposed as a way to improve 
the anticancer activity of these cholesterol based nanoparticles.  
A cholesterol-based block copolymer with a reducible disulfide bond (PC5MA-
SS-PEO) was then designed to overcome the slow intracellular drug release issue. We 
hypothesized that high tumor glutathione (GSH) concentrations can lead to the 
reduction of the disulfide bond in the polymer structure followed by nanoparticle 
disruption and subsequent drug release. Initially, we investigated the effect of the 
method of preparation and formulation parameters on the characteristics of redox-
sensitive nanoparticles containing doxorubicin (DOX-SS-NPs) as an approach to obtain 
nanoparticles with optimal particle size distribution, morphology and drug loading for in 
vivo administration. A significant influence of the method of preparation and formulation 
parameters on the properties of drug-loaded nanoparticles was observed and two 
formulations were selected for further in vitro evaluation.  
Subsequently, the redox-sensitive nature of nanoparticles prepared with PC5MA-
SS-PEO was confirmed by increased in vitro drug release in biologically relevant 
reducing conditions. Significant differences in the rate and extent of in vitro drug 
release, cytotoxicity activity in cancer cells and intracellular distribution of DOX were 
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observed between the evaluated Formulations (Formulation 2 and Formulation 4), 
indicating that the method of preparation can not only affect the properties of drug-
loaded nanoparticles but also their performance. Remarkably, in this in vitro testing 
stage, Formulation 4 proved to be significantly more potent than DOX-NPs (non-
cleavable nanoparticle) and Doxil®.    
Finally, one redox-sensitive formulation was selected based on the in vivo 
distribution of the nanoparticles; Formulation 4 was selected for efficacy studies 
because it displayed the best in vitro performance, effectively accumulated in tumor 
tissues and there were not tumor accumulation differences when compared to 
Formulation 2. Subsequently, the in vivo dose tolerability and efficacy of this selected 
formulation was evaluated in comparison to DOX-HCl and Doxil®. After tolerability and 
efficacy testing, it was clear that DOX-SS-NPs (Formulation 4) at a dose of 3 mg/kg was 
safer than DOX-HCl administered at the same dose and did not display the cardiac 
adverse effects and  fatal toxicity observed in mice treated with Doxil®. Encouraging 
results in terms of effective tumor growth inhibition were also observed. However, a 
study with a larger sample size is required to established, with proper statistical support, 
the potential differences when comparing to DOX-HCl and Doxil®. 
 
7.2 Conclusions and Future Perspective  
In this dissertation work, two novel doxorubicin-loaded cholesterol-based NPs 
(non-cleavable and cleavable) were formulated and extensively evaluated (in vitro and 
in vivo); both types of nanoparticles were efficacious, inhibiting tumor growth in an 
animal model, and also displayed better safety profiles than the free form of the drug.  
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These findings, support the development of nanomedicines as a valid strategy to 
improve the therapeutic index of highly toxic anticancer drugs. In addition, prove of the 
advantages associated to bioresponsive (cleavable) carriers was provided in this thesis, 
through comprehensive in vitro testing.  The experimental outcomes validate the use of 
the bioresponsive nanocarrier approach as a way to improve the efficacy of 
nanomedicines by facilitating drug release in the dissed tissue and the subsequent 
interaction between the drug and its intracellular target.  
On the other hand, extensive evidence of the significant influence of the method 
of preparation on the characteristics and performance of polymeric NPs was presented 
in this thesis, underlying the relevance of formulation optimization when developing this 
kind of nanomedicines. The impact of the method of preparation on the properties of 
nanomedicines has been previously reported by other research groups. However, the 
extent in which the method of preparation can also affect the performance of drug-
loaded nanoparticles was a knowledge gap addressed by this dissertation. These 
results support the adoption of a systematic quality by design approach for the 
formulation of this type of non-biological complex drugs, which is currently missing in 
academic research.  
Remarkably, the encouraging results observed when comparing doxorubicin-
loaded redox-sensitive nanoparticles (DOX-SS-NPs) vs Doxil® justify conducting future 
in vivo efficacy studies with larger sample size in order to establish differences between 
these two treatments with appropriate statistical support . Such studies may benefit from 
using a tumor model in which glutathione is over-expressed so the redox-sensitive 
properties of DOX-SS-NPs can be fully exploit. Additionally, efforts intended to scale up 
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the preparation of DOX-SS-NPs are needed in order to conduct the proposed future 
efficacy studies. 
Finally, in terms of future clinical application, DOX-SS-NPs could be a valuable 
therapeutic tool in the context of personalized medicine; patients with tumors displaying 
increased reducing status, which can be determined using redox-sensitive imaging 
probes, and suffering from cardiac comorbidities could greatly benefit from the 
administration of DOX-SS-NPs instead of DOX-HCl or Doxil®, as DOX-SS-NPs 
demonstrated increased drug release in reducing conditions and complete absence of 
cardiac toxicity.  
 
 
 
	
	
 
	
 
 
